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ABSTRACT 
 
 
Because transcription factor nuclear factor (NF)-κB plays an important role in vascular 
inflammation at blood-brain barrier, the present study constructed a novel DNA complex 
to specifically target endothelial NF-κB for inhibition of cerebral inflammation. This 
DNA complex (GS24-NFκB) contains two functional domains: a DNA Decoy for 
inhibiting NF-κB activity and a DNA aptamer (GS-24), a ligand of transferrin receptor 
(TfR), for targeted delivery of the DNA Decoy into brain endothelial cells. The results 
indicated that GS24-NFκB was delivered into murine brain-derived endothelial (bEnd5) 
cells and the delivery was specific and TfR-dependent. The DNA chimera inhibited 
inflammatory responses in the cells induced by tumor necrosis factor α (TNF-α) or 
oxygen-glucose deprivation/reoxygenation (OGD/R) via down-regulation of nuclear NF-
κB subunit, P65, as well as its downstream inflammatory cytokines, such as inter cellular 
adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule (VCAM-1). The 
anti-inflammatory effect of the GS24-NFκB was shown as significant reduction in 
monocyte adhesion to the bEnd5 cells induced by TNF-α or OGD/R after GS24-NFκB 
treatment. Pharmacokinetic study suggested its poor nuclease resistance and rapid 
clearance from systemic circulation. Organ uptake of GS24-NFκB including brain uptake 
was much higher compared to the scramble control and high organ uptake was observed 
in liver and spleen with high expression of TfR. The brain uptake is 0.39%ID/g, which is 
comparable to the brain uptake of anti-TfR monoclonal antibody, OX26 (0.44%ID/g).  
Intravenous injection of GS24-NFκB (15mg/kg) was able to significantly reduce the 
expressions of phospho-P65 and VCAM-1 in brain endothelial cells in mouse 
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lipopolysaccharide (LPS) induced inflammatory model, suggesting effective inhibition of 
activation and transcriptional activity of NF-κB. However, the disease-modifying effects 
of GS24-NFκB need to be further investigated in future. In conclusion, our approach 
using DNA nanotechnology has successfully delivered the therapeutic decoy into brain 
endothelial cells and induce pharmacological effect. It could be potentially applied for 
inhibition of inflammation in ischemic stroke and other neuroinflammatory diseases 
affecting cerebral vasculature.  
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CHAPTER 1 
 INTRODUCTION 
 
Central nervous system (CNS) is a complicated system which regulates and coordinates 
body activities. CNS disorders lead to various problems including mobility, mental tasks 
(learning and memory), basic functions (swallowing and breathing), or emotional 
changes in mood. CNS diseases are a leading cause of disability and affect over 1 billion 
people worldwide. Every year, over 6 million people died as a results of neurological 
disorders. Approximately 25% of people between 16 and 64 years of age suffer from a 
chronic neurological disability[1]. Unfortunately, these numbers are still rising. Although 
various factors contribute to the diseases, including vascular disorders, injury, toxin, 
infection and degeneration, one important event involved in many of these diseases is 
neuroinflammation. Neuroinflammation is characterized by activation of microglia and 
astrocytes, up-regulation of inflammatory mediator, disruption of the blood-brain barrier 
and infiltration of peripheral leukocytes. Neuroinflammation is initiated to protect brain 
from injury [2-4], but if unregulated, it may lead to secondary brain damage by itself[5]. 
Neuroinflammation has been implicated in various CNS diseases, including not only 
acute but also neurodegenerative diseases, e.g. stroke, multiple sclerosis (MS), 
Parkinson’s disease (PD) and Alzheimer’s disease[6-10].  
Inflammation of blood brain barrier (BBB) plays an important role in the onset and 
progression of neuroinflammation by triggering release of inflammatory mediators and 
enhancing the invasion of peripheral leukocytes [11, 12]. Those inflammatory mediators 
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include CD14 LPS receptor[13], interleukin-1(IL-1)[14], TNF [15-17], cyclooxygenase-
2[18], inducible nitric oxide synthase (iNOS) [19], adhesion molecules ICAM-1 and 
VCAM-1[20-22], etc. Up-regulation of the above pro-inflammatory molecules in cerebral 
endothelial cells damages the barrier function of the blood-brain barrier (BBB) [23, 24] 
and leads to neuronal injury and death. Compromise of BBB results in further activation 
and accumulation of  macrophages, microglia, leukocytes and other immune cells 
throughout the CNS, which is implicated in the development of neuronal injury and 
death[25, 26] . Importantly, up-regulation of proinflammatory and inflammatory 
mediators is closely related to activation of transcription factor NF-κB, which is a master 
switch of inflammatory gene expression [27, 28]. Activation of NF-κB induces the 
expression of inflammatory genes, such as adhesion molecules (ICAM-1, VCAM-1), 
iNOS and IL-1[29]. Notably, activation of NF-κB was also seen in the BBB endothelial 
cells under inflammatory conditions [30-33].  Based on the central role of NF-κB in 
inflammatory responses, we hypothesize that inhibition of NF-κB activity in cerebral 
endothelial cells will have suppressive effects on cerebral vascular inflammation as it 
targets multiple inflammatory signals instead of one inflammatory molecule. Therefore, 
cerebral endothelial transcription factor NF-κB could be a new potential therapeutic 
target for neuroinflammatory diseases such as ischemic stroke, MS and PD. It would be 
highly significant to design therapeutic interventions that specifically target endothelial 
NF-κB for restoration or modulation of the BBB functions, as this could improve the 
outcome of the diseases. 
In this study, NF-κB decoy serves as the therapeutic approach to inhibit transcriptional 
activity of NF-κB and subsequent inflammatory responses in brain endothelial cells. NF-
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κB decoy, a short double-stranded DNA oligonucleotide (ODN) binds to “cis”- binding 
sequence (6-10bp) of NF-κB preventing cis-trans interaction between NF-κB and the 
promoter region of the target genes. It has been shown that the NF-κB decoy was 
effective in modulating gene expressions under experimental conditions [34-38]. 
Importantly, the effectiveness of these decoy ODNs against gene expression involved in 
inflammatory responses in brain endothelial cells has been demonstrated by experiments 
in vitro[39-41]. Thus, inhibition of NF-κB activity in the brain endothelial cells using 
NF-κB decoy could be a potential therapeutic approach for neuroinflammatory disease. 
However, the therapeutic use of the oligonucleotides for brain diseases is strongly 
hampered by poor crossing of BBB. Most current approaches used for brain delivery of 
macromolecular drugs are invasive, like intra-cerebral injection, which cause brain tissue 
damage and possible infection[42]. Therefore, the development of non-invasive systemic 
delivery systems is critical to eventually achieve clinical applications of the DNA decoy 
approach, which can be achieved by taking advantage of receptor-mediated transport 
system present on BBB. In the present study, we used a DNA aptamer (GS-24, a ligand 
of TfR) as a vector to deliver NF-κB decoy into brain endothelial cells. The GS24, a 
DNA aptamer (Fig. 2), can specifically bind to the extracellular domain of mouse TfR 
(TfR-ECD) to be taken up by cells via TfR-mediated endocytosis. It has been 
successfully used to deliver a lysosomal enzyme into deficient cells to correct defective 
glycosaminoglycan degradation in the cells [43]. A novel DNA complex for brain 
delivery of NF-κB decoy with a goal to inhibit cerebral vascular inflammation was 
constructed, which contains two functional structures: GS24 aptamer for brain delivery 
and NF-κB decoy for anti-inflammatory effect. In the study, we have evaluated: (1) 
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delivery of GS24-NFκB in vitro and in vivo; (2) anti-inflammatory effect of GS24-NFκB 
under inflammatory and Oxygen Glucose deprivation/Reoxygenation (OGD/R) 
conditions in vitro; (3) pharmacokinetics and organ distribution in mouse; (4) anti-
inflammatory effect in mouse inflammatory model induced by LPS. 
Significance: It is well-known that a lot of efforts have been made to inhibit 
neuroinflammation but new drugs against neuroinflammation has been decreasing and 
results of clinical trials have been disappointing due to lack of significant therapeutic 
effect, obvious harmful side effects and limitation of brain delivery. The majority of anti-
inflammatory drugs include steroid-based glucocorticoid receptor agonists and 
nonsteroidal anti-inflammatory drugs (NSAIDs).  Glucocorticoids is effective in the 
treatment of MS via blocking the synthesis of inflammatory mediators by inhibiting NF-
κB activation [44]. However, due to the modulation of multiple non-immunological 
genes, prolonged use induces a variety of side effects, such as cardiovascular disease and 
osteoporosis. Moreover, the brain delivery is limited because of the export by the p-
glycoprotein (p-gp) efflux pump present on BBB [45].  NSAIDs inhibiting 
cyclooxygenases (COX) are widely used against inflammation. However, they showed 
lacked significant therapeutic effect in neuroinflammation [46-48] and significant CNS 
side effects, including aseptic meningitis, psychosis, and cognitive dysfunction [49, 50]. 
There is an urgent need to develop novel treatments against neuroinflammation. Our 
novel ODN-based brain drug delivery system presents several advantages. The cell-
specific and gene-specific therapeutic strategy can significantly promote therapeutic 
effect and reduce harmful side effect. The DNA conjugate only targets endothelial NF-κB 
and leaves neuroprotective effect of the neuronal NF-κB unaffected. The drug delivery 
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system only contains DNA, which limits immune response and rejection after repeated 
long-term drug administration, making them suitable for the therapy of chronic brain 
diseases[51, 52]. It can be chemically synthesized in large quantities with relatively low 
cost and amenable to various chemical modifications for improved serum stability and 
pharmacokinetics [52, 53]. The size of the DNA complex is relatively small compared to 
large molecules, which promotes tissue penetration [52, 54]. All these features make the 
gene delivery system very promising in the treatment of brain diseases. Moreover, most 
previous studies on neuroinflammation focused on the microglia, astrocytes and neurons.  
The present study explores the cerebral endothelial cell as a novel site of action for brain 
drug delivery and neuro-vascular inflammation therapy. 
Summary: The inflammation at BBB mediated by brain endothelial cells is critical to the 
onset and progression of neuroinflammation. Brain endothelial cells mediated 
inflammation by releasing inflammatory molecules, including cytokines, adhesion 
molecules, matrix metalloproteinase and nitric oxide, which are regulated by transcription 
factor NF-κB[11, 55]. In the present study, a dual functional oligonucleotide complex 
was generated to inhibit NF-κB dependent inflammatory responses, which contains two 
functional domains: GS24 aptamer targeting TfR on brain endothelial cells for brain 
delivery and NF-κB decoy targeting endothelial NF-κB for inhibiting inflammation at 
BBB. The DNA complex provides a site-specific and gene-specific strategy to inhibit 
neuroinflammation with low immunogenicity, which should be an effective approach to 
treat inflammation relevant brain diseases. The cellular uptake in vitro, pharmacological 
effect in vivo and in vitro, and pharmacokinetics and biodistriution of the DNA complex 
have been investigated in this study. 
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CHAPTER 2 
REVIEW OF THE LITERATURE 
 
2.1 Neuroinflammation 
Neuroinflammation is a double-edged sword. On the one hand, it is protective by 
regenerating brain tissues, isolating damaged tissues, and removing cell debris, especially 
in the early stage of inflammation[56]. On the other hand, once unregulated, the 
accumulation of free radicals, inflammatory molecules and leukocytes exacerbate the 
inflammation and lead to further neuronal dysfunction and loss[57]. It is well-known that 
brain is described as immune-privileged area due to the absence of lymphatic vessels and 
presence of BBB which controls the exchange of leukocytes and inflammatory 
mediators[58]. However, this immune privilege is not complete. Upon activated by 
various stimuli including injury, toxin and infection, microglia produce pro-inflammatory 
molecules and enhance expression of surface antigens even though they are immature 
antigen-presenting cells (APCs) in normal conditions[59-62]. And antigens can be 
drained into deep cervical lymph nodes by alternative routes despite of the absence of 
lymphatic vessels [12, 63]. In the presence of stimuli, brain endothelial cells are also 
activated and produce inflammatory molecules and free radicals and enhance the 
expression of adhesion molecules, which disrupt the blood-brain barrier and allow 
invasion of leukocytes and blood inflammatory molecules[11].  
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2.1.1 Blood-brain barrier 
BBB is the physical, metabolic and neurological barrier that separate the CNS from the 
peripheral circulation`. BBB is primarily formed by cerebral endothelial cells (CECs), as 
well as astrocytes, pericytes, perivascular macrophages and basal lamina [64, 65]. The 
structure of BBB is shown in Fig.1, where CECs are surrounded by a based lamina with 
astrocytes opposite on their end feet. Compared to peripheral endothelial cells, CECs 
have distinguished characteristics: (1) tight junction which is primarily composed of ZO-
1,occludin and claudin proteins to form the physical barrier[66]; (2) higher electrical 
resistance[67]; (3) absence of fenestrae[68, 69]; (4) high density of mitochondrial[69]; 
(5)absence of pinocytotic vesicular transport [68, 69]; (6) P-glycoprotein-mediated efflux 
pump which is associated with multidrug resistance(MDR) in tumors[70]. All these 
features of CECs contribute to its barrier function of restricting the entry of blood solute 
and leukocyte migration into CNS[11].  
Since BBB separates brain from peripheral system to maintain the homeostasis of the 
CNS, it is selectively permeable. The transport pathway through BBB is indicated in 
Fig.1[71].The physicochemical properties of the substances affect their transport across 
BBB, including lipid solubility, molecular weight and electrical charge. It is easier for 
low molecule weight, lipophilic and un-ionized molecules to pass through BBB [72, 73]. 
There are also various transport and enzymatic systems present on CECs to facilitate 
traverse of certain substances, such as glucose, serotonin and transferrin [74-76]. In 
addition, P-glycoprotein expressed on CECs actively transports substances from the CNS 
into systemic circulation to maintain the integrity of BBB[77]. Although BBB tightly 
controls the transport of blood components and cellular invasion in normal condition, the 
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permeability of BBB is significantly enhanced in inflammation due to disruption of tight 
junctions, or increased pinocytotic transport or formation of transendothelial channels, 
resulting in further inflammatory responses and neuronal injury. Therefore, the role of 
CECs at BBB in neuroinflammation cannot be ignored. 
 
 
Figure 1 Transport pathway through BBB. 
 
 
2.1.2 CECs-mediated inflammation  
Toll-like receptors (TLRs), a type of pattern recognition receptor, recognize structurally 
conserved molecules derived from pathogens and induce immune response such as 
inflammation. Major histocompatibility complex II (MHCII), cell surface molecules, are 
involved in presenting antigens to CD4+ T lymphocytes, activating and recruiting 
cytotoxic CD4+ T cells. Both of TLRs and MHC II are usually expressed on immune 
cells. However, it has been reported that their expressions were observed on CECs in 
CNS inflammatory diseases like multiple sclerosis [78, 79].In addition, BBB selectively 
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allows transport of some cytokines, such as IL-1 and TNF-α, indicating the presence of 
cytokine receptors on CECs, which has been verified by many studies[80-82].Therefore, 
CECs can be activated by both exogenous insults and endogenous cytokines due to the 
presence of antigen receptors and cytokine receptors on the cell surface. 
Upon activation, CECs mediate neuroinflammation through a variety of mechanisms. (1) 
In early inflammatory process, activated CECs produce important cytokines including 
TNF-α, IL-1 and IL-6[83]. These cytokines exacerbate inflammation by stimulating 
further release of cytokines and enhancing the permeability of BBB through 
reorganization of the actin-cytoskeleton and inducing expression of adhesion 
molecules[84, 85]. (2) Activated CECs promote expression of adhesion molecules, 
including selecins, integrins and the immunoglobulin (Ig) superfamily[86], which are 
responsible for rolling, tethering, adhesion and finally migration of leukocytes(Fig.2). 
Selectins and integrins bind to their ligands on leukocytes, resulting in weak adhesion 
between CECs and leukocytes [87, 88]. To achieve high affinity of binding, ICAM-1 and 
VCAM-1 recognize and bind to leukocytic ligands, lymphocyte functional antigen-
1(LFA-1) and very late antigen-4(VLA-4) respectively, which account for firm adhesion 
and permit the invasion of leukocytes[86, 89]. It was once supposed that leukocytes 
migrated through disrupted tight junction [90]. But more evidence indicated that the 
migration occurred through transcellular pathway[91]. Activation and accumulation of 
leukocytes release more deleterious mediators, which lead to further endothelial injury, 
opening of BBB and subsequently neuronal dysfunction and loss[92]. (3) Activated CECs 
produce matrix metalloproteinases (MMPs), a family of proteolytic enzymes [93, 94]. 
MMPs degrade basement membrane of CECs and contribute to the opening of BBB[95]. 
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(4) Activated CECs release arachidonic acid metabolism, including prostaglandins, 
leukotrienes and superoxide ion, which contribute to activation of leukocytes, secretion 
of cytokines and cell membrane damage of CECs[24, 96, 97]. (5) Activated CECs 
produce free radical nitric oxide (NO), resulting in BBB dysfunction[98]. However, the 
mechanism is not clear. In summary, CECs play an essential role in the onset and 
progression of neuroinflammation. 
 
 
Figure 2 Adhesion molecule-mediated migration of leukocytes. 
 
2.2 NF-κB 
Among various inflammatory mediators involved in the inflammatory responses at BBB, 
NF-κB, a dimeric transcription factor, is one of the most important ones[99, 100] as up-
regulation of inflammatory molecules is closely related to the activation of NF-κB. It is 
well-known that correct modulation of gene expression is essential to the normal 
functions of cells and organs. Transcription factors are such kind of regulatory proteins 
which regulate transcription of specific genes. Good understanding of transcription 
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factors has given an insight of pathophysiology of various diseases and offered novel 
therapeutic targets.  
In mammals, five different NF-κB subunits, P50, P52, c-Rel, RelA (P65) and RelB form 
homo and heterodimers in various combinations[101, 102]. P50/P65 dimer is the most 
abundant one and found in almost all cell types. NF-κB is expressed in almost all cell 
types and a large number of genes contain the specific NF-κB binding sites in their 
promoters/enhances. NF-κB regulates the expression of these genes in cell-type- and 
situation-specific manner. Due to its effect on a wide range of genes, regulation of its 
activity is tightly controlled at multiple levels[55]. The canonical pathway is regulated by 
IκB proteins, which contain several members, IκBα, IκBβ, IκBε, P100 and P105. P100 
and P105 are the precursor proteins of P52 and P50 respectively[100]. IκB proteins 
preferentially bind to certain subsets of NF-κB dimers. For example, IκBα has high 
binding affinity for P65/P50 dimer [103]. IκB interacts with NF-κB and masks its nuclear 
translocation signal and thus sequesters NF-κB in cytoplasm[104]. But upon stimuli 
including infections, stresses, free radicals and cytokines, such as IL-1 and TNF-α, IκB 
proteins are phosphorylated by IKK (IκB kinase) complex, rapidly ubiquitinated and then 
degraded by cytosolic proteasome[105]. IKK complex is composed of two catalytically 
active kinases, IKKα and IKKβ, and the regulatory subunit IKKα (NEMO) [106, 107]. 
Degradation of IκB allows NF-κB free to translocate to nucleus and activate transcription 
of target genes by binding to specific DNA sequences[100](Fig.3).  
To obtain a maximal NF-κB response, post-translational modifications serve to regulate 
NF-κB activity, including phosphorylation, ubiquitination and acetylation [108].It has 
been reported that phosphprylation of P65 at Ser536 definitely contributed to the 
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transcriptional activation of NF-κB but the mechanism was not clear[55]. One possible 
mechanism is that phosphorylated P65 (Ser536) facilitate the recruitment of 
transcriptional coactivators [108]. It was also indicated that phosphorylation of P65 
(Ser536) was involved in regulation of P65 nuclear localization[109]. The  
 
Figure 3 The mechanism of NF-κB activation and inhibitory effect of GS24-NFκB. 
 
phosphorylation occurred in both nucleus and cytoplasm through different kinases [110]. 
It seems that translational modifications are crucial in target-gene specificity and timing 
of gene expressions.  
In additional to activation, the termination of NF-κB is also modulated in various 
manners. IκB proteins are themselves NF-κB-dependent genes, resulting in the auto-
regulatory feedback loop[111]. Generated IκB entered the nucleus and exported NF-κB to 
cytosol. Translational modifications of NFκ-B subunits also contributed to termination of 
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NF-κB response through alteration of co-factor binding or degradation of NF-κB[112]. 
Moreover, DNA-bound P65 can be ubiquitinated and degraded by proteasome. 
NF-κB is known as its crucial role in inflammation regulation through NF-κB-dependent 
transcription of cytokines, chemokines, adhesion molecules and acute phase proteins [29, 
113]. Activation of NF-κB is a key event in many CNS diseases such as ischemic stroke, 
MS and neurodegenerative diseases [99, 113, 114], which make NF-κB a potential target 
for these diseases. A lot of evidence indicated that NF-κB was activated in various cells 
in cerebral ischemia, including neurons, CECs, astrocytes and microglia[99]. Although 
the effect of NF-κB activation on outcome of cerebral ischemia is not determined, many 
studies have proven that inhibition of NF-κB signaling did have neuroprotective effect. 
Estrogen receptor and the peroxisome proliferator-activated receptor γ (PPARγ) showed 
well-established neuroprotection by inhibition of NF-κB[115, 116]. In addition, a variety 
of selective IKK inhibitors which inhibited nuclear translocation of NF-κB were found to 
be protective in animal model of stroke [117]. NF-κB activation was also observed in MS 
brain cells, including astrocytes, oligodendrocytes, microglia, and infiltrating 
macrophages in or near CNS lesions [118, 119]. NF-κB-dependent genes were up-
regulated in MS brain [120, 121]. It has been demonstrated that inhibition of NF-κB was 
protective in treatment of MS. Glucocorticoids (CGs) are the most widely-used and long 
established immunosuppressive drugs, which have the ability to suppress transcriptional 
activity of NF-κB by increasing expression of IκB and block the nuclear translocation of 
NF-κB[122, 123]. In MS treatment, CGs improved disability and facilitated lesion 
recovery[124]. Activation of NF-κB is also a critical event in neurodegeneration diseases, 
such as PD [113]. NBD (NEMO-binding domain) peptide, which blocked the assembly 
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of IKK and thus suppressed the activation of NF-κB, had effect in reversing the 
neurodegeneration in murine model of PD by protecting TH+ (tyrosine hydroxylase ) 
neurons from degeneration, reducing loss of dopamine production and improving 
locomotor function of mice[125].  
Although most of these studies focused on neurons, microglia and astrocytes, activation 
of NF-κB was also reported in the BBB endothelial cells in inflammatory conditions 
[126, 127] and inhibition of endothelial NF-κB activity effectively reduced expression of 
adhesion molecules and monocyte adhesion to brain endothelial cells. As mentioned 
above, brain endothelial cells mediated inflammation through releasing inflammatory 
molecules, including cytokines, adhesion molecules and MMP, which are regulated by 
NF-κB as they are NF-κB target genes. Moreover, inhibition of NF-κB reduced the 
synthesis of inducible NO synthase, which subsequently decreased the release of NO. 
Therefore, inhibition of endothelial NF-kB would be an attractive therapeutic strategy for 
inhibiting the inflammation of BBB, blocking leukocyte migration and finally reducing 
the neuronal injury.  
2.3 Oligonucleotide therapy 
In recent years, oligonucleotides (ODNs) as a powerful tool for modulation of gene 
expression, have gained considerate attention. They provide a rational way to design 
sequence-specific ligands of nucleic acids or DNA-binding regulatory proteins for 
selective regulation of gene expression.  The same approach may be used to design drugs 
against many disease since each site of action of nucleic acids in cells presents an 
opportunities for therapeutic intervention. There are three classes of therapeutic ODNs: 
(1) ODN hybridizing to RNA, including antisense ODN, siRNA and ribozymes and 
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DNAzymes; (2) ODN hybridizing to DNA, including locked nucleic acid (LNA) and 
peptide nucleic acid (PNA) ;( 3) ODN hybridizing to proteins or small molecules, 
including aptamers and decoys[128]. The ODN therapy has been tested and developed 
not only in pre-clinical experiments but also in clinical trials. The first FDA approved 
antisense ODN, Fomivirsen (1999), is used to treat cytomegalovirus retinitis (CMV), 
which is a synthetic ODN with phosphorothioate linkages to enhance resistance to 
degradation by nucleases. Fomivirsen blocked the translation of viral mRNA by binding 
to the mRNA transcribed from a key CMV gene[129].  
2.3.1 Transcription factor decoy 
Transcription factors are able to recognize and bind to relatively short binding sequences 
even without surround genomic DNA[130]. The consensus binding site of specific 
transcription factor can be developed as tools for modulation of gene expression. 
Transcription factor decoys are short, double-stranded oligonucleotides, which mimic the 
sequences of the binding sites in promoter/enhancer region of target genes [131]. The 
decoys result in a significant reduction in or even a blockade of transcriptional activation 
by interacting with transcription factors and luring them away from DNA binding sites, 
which offer a powerful tool to manipulate gene expression [128, 131]. The decoy was 
first described to regulate gene expression in 1990 by Bielinska el at..[34]. Decoys 
specific to octamer transcription factor and NF-κB successfully inhibited their binding 
activity in nucleus and octamer-dependent activation of a reporter plasmid or NF-κB-
dependent activation of the human immunodeficiency virus (HIV) enhancer. Decoy was 
first used as a therapeutic approach in 1995 by Morishita el at.. The transcription factor 
E2F is involved in the regulation of cell cycle-regulatory genes and the gene encoding 
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proliferating-cell nuclear antigen (PCNA). E2F decoy was employed in the treatment of 
rat carotid injury, which inhibited the expression of the above genes and blocked smooth 
muscle cell proliferation and neointimal hyperplasia in injured vessels[132].  
In the last several decades, with a growing number of transcription factors which have 
been identified, decoys have gained more and more attention to become a potential 
therapy for broad clinical application. Various decoys targeting transcription factors 
including NF-κB, CREB (cAMP-response element–binding protein), activator protein 
1(AP-1) and signal transducers and activators of transcription-1 (STAT-1) have been 
generated and the effectiveness of these decoys has been demonstrated. CREB decoy 
affected CRE binding activity and inhibited cancer cell growth in vitro and in vivo. And 
the inhibition appeared to be tumor-specific since the growth of normal cells were not 
affected, which indicated that CREB-decoy may be developed as a potential strategy 
treating cancers by regulating the expression of cAMP-sensitive genes[133]. AP-1 plays 
an important role in neointimal formation after vascular injury. AP-1 decoy inhibited the 
proliferation and migration of VSMCs in vitro and blocked neointimal formation after 
balloon injury to the rat carotid artery [134]. STAT-1 mediates CD40 expression in 
human endothelial cells, which play an important role in acute cellular rejection in small 
bowel transplantation. STAT-1 decoy suppressed CD40 expression and thus improved 
mucosal perfusion, and reduced graft rejection, T-cell infiltration and apoptosis in rat 
small bowel allografts during acute rejection[135]. 
2.3.2 NF-κB decoy  
NF-κB decoy is one of the most widely used decoys, which suppresses NF-κB activation 
and blocks NF-κB-dependent signaling. Due to the multiple functions of NF-κB in cells, 
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NF-κB decoys have been used in a wide variety of diseases, including cardiovascular 
diseases, cancer, asthma, rheumatoid arthritis (RA), skin diseases and other inflammatory 
diseases[136-141]. For example, rheunatoid arthritis is known as a chronic, systemic 
inflammatory disorder affecting the synovial joint. NF-κB was found to be essential to 
coordinate transactivation of cytokines related to the pathogenesis. Tomita et al. 
transfected synovial cells with NF-κB decoy in vitro, which significantly inhibited the 
expression of inflammatory mediators, including IL-1β, IL-6, TNF-α, ICAM-1 and 
MMP. Then NF-κB decoy was introduced by an intraarticular injection into rat joints in 
RA model. The production of IL-1 and TNFα in the synovium of arthritic joints were 
reduced and a marked suppression of joint destruction was observed [141].  
NF-κB decoy has also been proven to have anti-inflammatory effect in brain disease 
models. In a rat neuropathic pain model, the NF-κB decoy blocked the activation of NF-
κB and abolished the binding activity. Single endoneurial injection of NF-kB decoy, at 
the site of nerve lesion, significantly alleviated thermal hyperalgesia for up to 2 weeks 
and reduced the mRNA level of the inflammatory cytokines, iNOS, and adhesion 
molecules at the site of nerve injury[142]. In global brain ischemia, hemagglutinating 
virus of Japan–liposome complex with NF-κB decoy oligonucleotides, which was 
injected through carotid artery at 1 hour after ischemia, inhibited the mRNA expression 
of TNF-α, IL-1β and ICAM-1 and significantly attenuated the neuronal damage[143]. In-
vitro study has demonstrated that delivery of NF-κB decoy into brain-derived endothelial 
cells (bEnd5 cell) affected NF-κB binding activity and decreased mRNA and protein 
level of inflammatory molecules (ICAM-1, VCAM-1 and iNOS) as well as reduced the 
adherence of bEnd5 cells to monocytes[126, 127]. Wang et al. developed a NF-κB decoy 
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loaded polylactic acid (PLA) nanoparticle, which was taken up by rat primary brain 
endothelial cells and localized in cytoplasm. The released decoys retained their biologic 
activity and reduced expression of tissue factor expression [144]. In summary, all the 
above studies indicated that NF-κB decoy could be a promising strategy against the 
neuroinflammation. 
2.4 Receptor-mediated brain delivery  
Although ODN therapy offers advantages over conventional drugs, the delivery of ODN 
to the desired cell type, tissue or organ is the biggest obstacle to overcome, especially for 
BBB which restricts the movement of drugs into the brain. To date, invasive and 
noninvasive approaches have been applied to the delivery of drugs that do not have an 
appreciable BBB permeability. Invasive delivery, including direct intracranial injection, 
intraventricular administration and BBB disruption, causes brain tissue damage and 
possible infection[42]. Therefore, the development of non-invasive systemic delivery 
systems is critical to eventually achieve clinical applications of the DNA decoy approach. 
Noninvasive brain delivery can be achieved by taking advantage of endogenous transport 
system present at the BBB [145]. There are two main classes of transport system, carrier-
mediated transport and receptor-mediated transport (RMT). Carrier-mediated transport 
systems are typically small, stereospecific pores and not applied to delivery of large 
molecules such as ODN and proteins [145]. RMT system has been used for targeted 
delivery of a variety of drug cargoes, such as small molecules, proteins, genes, and drug-
loaded particles [145]. The therapeutic carrier of interest can be conjugated to a ligand 
targeting receptor-mediated transport system. Once binding to specific ligands, the cell 
surface receptors mediated endocytosis and delivered the therapeutic agents into cells. 
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This approach requires nothing more than an intravenous injection to allow for targeted 
delivery. The most important aspect of this approach is the choice of receptors and their 
ligands. Various receptors on BBB have been reported for drug delivery, including 
transferrin receptor (TfR) [146, 147], insulin receptor[148, 149], insulin-like growth 
factor receptor[150], low density lipoprotein receptor-related protein[151] and tumor 
necrosis factor[152].   
2.4.1 Transferrin receptor 
The transferrin receptor, a membrane glycoprotein, is involved in receptor-mediated 
uptake of transferrin-bound iron, which is expressed ubiquitously in the body, including 
red blood cells, erythroid cells, hepatocytes, intestinal cells, monocytes and brain 
endothelial cells. Briefly, the process is initiated by the binding of Fe-transferrin to TfR, 
followed by clathrin-dependent endocytosis. Fe-Tf and TfR are opsonized in clathrin-
coated vesicles and then trafficked to endosomes which mature in a unidirectional 
manner from early endosomes to late endosomes and finally fuse with lysosomal 
vesicles. At low PH 5.5 in endosomes, iron is released from Fe-Tf/TfR complex and 
transported out of endosome. The resultant Tf/TfR complex recycles back to cell surface 
and then at extracellular physiological PH7.4, Tf dissociates from TfR and goes back to 
systemic circulation as well as mediates another round cycle of iron uptake. The cycle of 
TfR-mediated cellular iron uptake is shown in Fig.4 [153]. 
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Figure 4 TfR-mediated endocytosis 
 
TfR is highly expressed on brain endothelial cells and the transport of Fe-Tf/TfR 
complex from the blood into the cerebral endothelial cells is not different in nature from 
the uptake into other cell types [154, 155]. Taking advantage of the endocytosis process 
and high expression on BBB, TfR becomes a promising target for brain drug delivery. In 
the beginning, Tf itself has been used as a ligand for brain delivery. Antiviral drug 
azidothymidine (AZT) was encapsulated into PEGylated albumin nanoparticle (PEG-
NPs), which was modified with Tf as a ligand for brain targeting. Tf anchored PEG-NPs 
significantly enhanced the uptake in brain tissue and brain localization of AZT compared 
with unmodified PEG-NPs [156]. However, since TfR is almost saturated with 
endogenous Tf, Tf is not an ideal ligand for brain delivery. Efforts have been made to 
develop monoclonal antibody (MAb) against TfR as alternative ligands, of which binding 
site is different from that of Tf. These antibodies have been widely used in brain drug 
delivery in the treatment of various brain diseases, which is known as receptor-mediated 
brain delivery with Molecular Trojan Horses. TfRMAb-TNFR fusion protein was 
generated by fusing TNF decoy receptor to TfRMAb against mouse TfR. The fusion 
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protein was rapidly transported into mouse brain in vivo after intravenous administration 
[157]. Then the fusion protein was used to treat acute brain ischemia in mouse. 
Intravenous administration of the fusion protein significantly reduced hemispheric, 
cortical, and subcortical stroke volumes, and neural deficit [158]. Erythropoietin (EPO), 
reducing oxidative stress in brain, was fused to TfRMAb against TfR to form a brain 
penetrating cTfRMAb-EPO fusion protein. Following 3 weeks of treatment with 
intravenous injection of the fusion protein, PD mice showed a 306 % increase in striatal 
TH enzyme activity and improvement in neuro-behavior [159]. Based on the above 
previous studies, TfR, currently one of the most developed RMT-based transport system, 
should be a good transport target in this study. 
2.5 Aptamer-mediated gene therapy 
2.5.1 Aptamers  
After choosing an appropriate RMT system, the next step is to find targeting ligand. 
Ligands generally contain antibodies, peptides, small molecules, and aptamers[160]. In 
this study, we used aptamer targeting TfR to delivery NF-κB decoy into brain endothelial 
cells. Aptamer are oligonucleotides selected in vitro from complex nucleic acid libraries 
by a process called SELEX (systematic evolution of ligands by exponential enrichment) 
to bind target molecules with high affinity and specificity because of their stable three-
dimensional structure [52]. It has been more than 20 years since aptamer was first 
described. Over the last decades, aptamers have been successfully developed as 
therapeutic or diagnostic approaches. For example, Pegaptanib (brand name Macugen) is 
a pegylated anti-vascular endothelial growth factor (VEGF) aptamer, which was 
approved by FDA in 2004 to treat neovascular (wet) age-related macular degeneration 
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[161]. Due to its ability to bind to cell surface receptors with high affinity and specificity 
and subsequently induce cellular endocytosis, the application of aptamer in drug delivery 
has attacked more and more interests.  
Compared to other ligands, aptamer have several advantages. (1) Aptamer has much 
higher targeting selectivity than small molecules such as folic acids although they have a 
low molecular weight and good stability [162, 163]. (2) Peptides are unstable and 
degraded easily in systemic circulation while aptamer is amenable to chemical 
modification to improve its serum stability and pharmacokinetics [164, 165]. (3) 
Although both aptamer and antibody show high affinity and specificity to targets, 
aptamers have better tissues penetration due to lower molecular weight [52, 166]. (4) 
Antibody often induce strong immune responses, especially following repeat injections 
while aptamer has limited immune response and rejection after repeated long-term drug 
administration [166, 167]. (5) Aptamer is more thermal stable than antibody. Aptamer is 
able to regain its 3D conformation once cooled to the room temperature after 
denaturation at 95 °C while antibody is permanently inactivated at high temperature 
[166]. (6) Compared to antibody, aptamer can be chemically synthesized in large 
quantities with lower cost. All these features make aptamer a popular ligand for targeted 
drug delivery. 
2.5.2 Aptamers in drug delivery 
Many of aptamers have been selected, identified and used in targeted drug delivery for 
the treatment of various diseases. These aptamers target a variety of cell surface 
receptors, including prostate-specific membrane antigen (PSMA)[168-173], nucleolin 
[174, 175], mucin-1(MUC1) [176], epidermal growth factor receptor (EGFR) [177, 178], 
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HIV protein gp120 [179, 180], and TfR [43, 181]. PSMA aptamer A10 and its truncated 
secondary generation A10-3.2, conjugated with siRNAs targeting prostate cancer–
specific pro-survival genes, successfully targeted PSMA-expressing tumors and inhibited 
tumor growth in vitro and in vivo [168, 169]. Boyacioglu et al. identified a new DNA 
aptamer and developed dimeric aptamer complexes (DACs) for specific delivery into 
PSMA-positive tumor cells [171]. Nucleolin aptamer AS1411 has been demonstrated to 
not only have anti-tumor effect itself but also facilitate tumor-specific delivery of cargoes 
to enhance their anti-tumor effect and reduce side effect [174, 175, 182]. Mucin-1 and 
EGFR aptamers also mediated tumor-targeted delivery [176, 177]. Aptamer (UCLA1) 
targeting gp120 expressed on human immunodeficiency virus-1(HIV-1), has been 
employed to deliver anti-human immunodeficiency virus (anti-HIV) siRNAs into HIV-
infected cells [179].  
Aptamers targeting TfR: Chen et al. first selected and isolated a DNA aptamer (GS24) 
(Fig.5a) and a RNA aptamer (FB4) (Fig.5b) targeting mouse TfR. To investigate its role 
in mediating endocytosis, the two aptamers were modified with biotin, followed by 
linked to dye-labeled streptavidin for detection by confocal microscopy. The aptamer-
streptavidin conjugates have been successfully internalized into mouse fibroblasts (Ltk− 
cells) and the internalizations appeared to be specific since they were inhibited by an 
excess of free aptamers. Moreover, the uptake was mouse TfR-dependent because the 
conjugates were not taken up by human cells (293T) unless they were firstly transfected 
with mouse TfR. The fact that the internalization was not inhibited by transferrin at a 
concentration similar to that found in mouse serum indicated that the two aptamers bind 
to extracellular domain of the mouse TfR which was different from the binding site of 
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transferrin, therefore avoiding competition for binding site with Tf and limiting effects on 
normal functions of TfR.  In addition, aptamer-streptavidin followed a different cellular 
trafficking path from transferrin. After 30min of endocytosis, transferrin was not 
observed in cells since it released the iron and recycled back to cell membrane while the 
conjugates colocalized with dextran-labeled lysosomes. They indicated that the 
endocytosis of the conjugates were still mediated by coated pits because it was not 
inhibited by methyl-β-cyclodextrin, an agent inhibiting alternative endocytic pathway by 
lipid rafts and caveolae. In the treatment of lysosomal storage diseases, GS24 was 
conjugated with a lysosomal enzyme, which successfully delivered the enzyme into 
lysosomes and relieved the enzyme deficiency [43]. In our previous study, ICAM-1 
siRNA was internalized into brain-derived endothelial cells (bEnd5 cells) via RNA 
aptamer FB4-mediated endocytosis and the siRNA effectively blocked the expression of 
target gene [181]. Because of high expression of TfR on brain endothelial cells, TfR 
aptamer have become a promising brain delivery approach to overcome the challenge of 
blood-brain barrier (BBB). In summary, it is very important to choose the perfect target 
for aptamer-mediated drug delivery to achieve high target specificity, which should be 
highly expressed on the target cells but not or lowly expressed on the surface of nontarget 
cells. 
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Figure 5 The structures of (a) GS24 and (b) FB4 aptamer 
2.5.3 Aptamer-therapeutic ODN conjugates 
Aptamer has been widely used in targeted delivery of ODN-based therapeutic molecules, 
including siRNA, miRNA, shRNA and decoy ODN. Aptamer can be connected with 
therapeutic ODNs noncovalently or covalently.  
In noncovalent conjugates, connectors have been employed, including streptavidin, GC-
rich “sticky sequence”, and packaging RNA. Taking advantage of high binding affinity of 
streptavidin for biotin, Chu et al. generated an aptamer:streptavidin:siRNA conjugate, in 
which two biotinylated-PSMA aptamer A9 were connected to two biotinylated siRNA 
via one molecule of streptavidin as a connector(Fig.6a). The conjugated was proven to be 
taken up by PSMA-positive cells and lead to gene silencing in these cells [168].  Zhou et 
al. developed a gp120 aptamer-anti-HIV siRNA conjugate with a sticky bridge. 3′-end of 
the aptamer and one of the two siRNA strands were chemically synthesized with a 3′ 7-
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carbon linker (7C3), which in turn was attached to a 16-nucleotide 2′ OMe/2′ Fl GCrich 
complementary bridge sequences. Then the aptamer-siRNA noncovalent conjugate can 
be formed via Watson-Crick base-pairing by simple mixing (Fig.6b). siRNA was 
demonstrated to be released from the conjugate and  trigger RNAi. Systemic 
administration of the conjugates inhibited HIV-1 viral load in viremic RAG-hu mice and 
did not induce any innate inflammatory cytokine production [180]. In our previous study, 
packging RNAs (pRNAs), derived from bacteriophage phi29 was used as a vector to link 
ICAM-1 siRNA and TfR aptamer (FB4) as a conjugate (Fig.6c). pRNAs contain two 
functional domains: the double-stranded helical domain at 5’/3’ end and the 
intermolecular binding domain . These two domains fold independently, and change of 
the primary sequences of helical region doesn’t affect pRNA structure and folding as 
long as the two strands are paired. Therefore, the helical region at the 5’/3’ end of pRNA 
can be replaced by siRNA or aptamer without affecting the formation of RNA multimers 
mediated by base-pairing of upper and lower loops in the intermolecular binding domain. 
Our siRNA-pRNA-aptamer chimera have been specifically delivered into TfR-positive 
bEnd5 cells but not TfR-silenced cells. siRNA was released from chimera by dicer 
cleavage, which successfully blocked the expression of ICAM-1[181].  
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(c) 
Figure 6 Schematic representation of noncovalent aptamer-ODN conjugate. (a) Apatmer-
streptavidin-siRNA conjugate, (b) Aptamer-sticky bridge-siRNA conjugate, (c) Aptamer-
pRNA/pRNA-siRNA conjugate. 
Aptamer-ODN covalent conjugates only involve nucleic acids, which largely reduces 
immunogenicity, making it suitable for in vivo application. McNamara et al. first 
generated a completely RNA-based A10-siRNA chimera, which targeted PSMA and 
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delivered therapeutic siRNAs against two survival genes PLK1 (polo-like kinase 1) and 
BCL2 (B-cell lymphoma-2) to tumor cells. The DNA encoding A10-siRNA was prepared 
and then A10-siRNA conjugate was obtained by transcription, in which 2’-fluoro 
modified A10 was covalently linked to the sense strand of siRNA and then annealed with 
the guide strand. The chimera was specifically taken up by PSMA expressing cells and 
siRNA was released by dicer to suppress the expression of target genes and induce cell 
death. In a xenograft model of prostate cancer, intratumoral delivery of the chimera 
displayed anti-tumor effect [53]. Then the chimera was optimized by Dassie et al. to 
obtain anti-tumor activity following systemic administration. A10 was replaced by its 
truncated version A10-3.2 for easier chemical synthesis.  2-nt (UU)-overhang was 
introduced at the 3’ end of the siRNA duplex for better recognition by dicer and 
passenger and guide strands of the siRNA were swapped to facilitate 5’ terminal 
modifications of the shorter RNA strand without loss of function. To enhance the 
circulating half-life, a 20 kDa PEG was appended to the 5’-terminus of the smaller RNA 
strand without affecting chimera targeting and silencing (Fig.7) [169]. 
 
Figure 7 Schematic representation of covalent aptamer-siRNA-PEG conjugate. 
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CHAPTER 3  
AIMS OF THE STUDY 
The overall objective of the study was to develop a novel gene brain delivery system to 
inhibit neuroinflammation by blocking the activation of inflammatory mediator, NF-κB. 
This work has potential applicability to the development of therapies for 
neuroinflammation relevant CNS diseases. We hypothesize that the DNA complex 
(GS24-NFκB) containing GS24 aptamer for brain delivery and NF-κB decoy for blocking 
NF-κB activation, is able deliver NF-κB decoy into brain endothelial cells via TfR-
mediated endocytosis and the delivered decoy is able to inhibit transcriptional activity of 
NF-κB and NF-κB dependent inflammation.  
1, The first aim was to evaluate the cell uptake of GS24-NFκB. The capability and 
specificity of the cellular uptake were studied. 
2, The second aim was to identify the pharmacological effect of GS24-NFκB in two in 
vitro inflammatory models: TNF-α model and OGD/R model. The activation and 
transcriptional activity of NF-κB were investigated. 
3, Under the third aim, the pharmacokinetics and organ distribution of GS24-NFκB were 
defined following systemic administration. 
4, Our fourth aim was to identify the pharmacological effect of GS24-NFκB in mouse 
LPS-induced inflammatory model. The activation and transcriptional activity of NF-κB 
in isolated brain microvessels were measured and neurological deficiency were studied. 
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CHAPTER 4 
MATERIALS AND METHODS 
 
4.1 Cell culture 
The brain endothelial cell line (bEnd5) derived from mouse brain and immortalized with 
polyoma middle T oncogene was gifted by Dr. Ulrich Bickel, Texas Tech University. 
bEND5 cells were grown in Dulbecco's modified Eagle's medium (DMEM) (Hyclone, 
Logan, UT, USA) supplemented with 10% (v/v) heat-inactivated fetal bovine 
serum(FBS) (Atlanta Bio InC. GA, USA), 1% (v/v) non-essential amino acids and 1% 
(v/v) 10000IU/ml penicillin/ 10000µg/ml streptomycin (all from ATCC, Manassas, VA, 
USA). U937 cells (a monocyte cell line from ATCC, Manassas, VA, USA) were cultured 
in RPMI 1640 medium (Hyclone, Logan, UT, USA) supplemented with 2 mM L-
glutamine (Mediatech Inc. Cellgro, Manassas, VA, USA), 10% heat-inactivated FBS and 
1% (v/v) 10000IU/ml penicillin/ 10000µg/ml streptomycin. Both cell lines were 
maintained at 37 °C, 5% CO2 and 95% relative humidity.  
4.2 Animals 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee at University of Cincinnati and they complied with pertinent NIH guidelines 
for care and use of animals. CD1 Male mice (body weight ~25g) supplied by Charles 
River (Wilmington, MA, USA) were kept under standardized light/dark (12 hours), 
temperature (22°C), and humidity (70%) conditions, with free access to water and 
standard pelleted food.  
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4.3 Preparation of GS24-NFκB complex 
The sequence of GS24-NFκB is: 
GS24-NFκB-decoy-1 strand:5’- GCG TGT GCA CAC GGT CAC TTA GTA TCG CTA 
CGT TCT TTG GTT CCG TTC GGC CTT GAA GGG ATT TCC CTC C -3’ 
NF-κB decoy-2 strand: 5’-GGAGGGAAATCCCTTCAAGG-3’. 
The sequence of scramble GS24-NFκB is: 
Scramble GS24-NFκB -decoy-1 strand:5’- AAG AGA GTA AAT CCT GGG ATC ATT 
CAG TAG TAA CCA CAA ACT TAC GCT GGC CTT GAA GGG ATT TCC CTC C-
3’.  
NF-κB decoy-2 strand: 5’-GGAGGGAAATCCCTTCAAGG-3’ 
The sequence of NFκB-decoy is[35]: 
NFκB-decoy -1 strand: 5’-CCT TGAAGGGATTTCCCTCC-3’. 
NF-κB decoy-2 strand: 5’-GGAGGGAAATCCCTTCAAGG-3’ 
The designed sequences of the strands above were purchased from Integrated DNA 
Technologies Inc (Coralville, Iowa, USA). The ODN complex was constructed by DNA 
denaturation and annealing process. Briefly, the mixture of two complementary strands 
(mole ratio 1:1) in annealing buffer (10mM Tris, PH 7.5-8.0, 50mM NaCl, 1mM EDTA) 
was incubated at 95°C for 5 min, and then cooled at the room temperature for 45-60 min. 
The DNAs were analyzed by 8% native-PAGE gel.  
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4.4 Cellular uptake of GS24-NFκB by bEnd5 cells 
4.4.1 Flow cytometry 
GS24-NFκB and naked NF-κB decoy were labeled with Cy3 using the Mirus Label IT 
Cy3 labeling kit (Mirus bio LLC., Madison, WI, USA) according to the manufacturer’s 
instructions. BEnd5 cells were seeded in 12-well plates 24 hours before adding Cy3 
labeled DNAs. Cells were incubated with DNAs for 30mins at 37°C and then washed, 
trypsinized, pelleted and suspended in FACS Buffer (PBS, 0.5% BSA and 2mM 
EDTA)[183]. The cell suspension was kept on ice and analyzed on a FACSCaliburTM 
flow cytometer (Becton Dickinson, Mountain View, CA).  
4.4.2 TfR (CD71) siRNA transfection 
The TfR negative bEnd5 cells were generated by transfecting CD71 siRNA with 
lipofectamine RNAiMAX (Life Technology, Grand Island, NY) according to 
manufacturer’s protocol.  
4.4.3 Quantitative cellular uptake of 32P-labeled DNAs 
GS24-NFκB and its scramble control were 5’-end labeled with [γ-32P] ATP (PerkinElmer 
Inc.,Waltham, Massachusetts, USA) using T4 Polynucleotide Kinase (Fermentas, USA) 
according to the manufacturer’s instructions, and then purified by  NucAway™ spin 
column (life technology,  Grand Island,NY). The purity of the product was controlled by 
precipitation of the ODNs with trichloroacetic acid (TCA) (Sigma-Aldrich Co.LLC., St. 
Louis, MO, USA), and only the batches with precipitation >95% were used [184]. 
Briefly, ice-cold 10% TCA (500µl) was added to a mixture of 1 μl sample and 50µl 2.5% 
bovine serum albumin (BSA, Fisher Scientific, Pittsburgh, PA, USA). The resulting 
mixture was then vortexed and incubated on ice for 10 min following by centrifugation at 
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4000g for 5 min. The supernatant was collected and the pellet was dissolved in 3% KOH. 
The radioactivity of TCA-precipitable fraction was calculated as % (precipitable fraction) 
= (CPMpellet X 100)/ (CPMpellet +CPMsupernatant).  
The TfR negative and normal bEnd5 cells with 80-90% confluence were incubated with 
32P-labeled DNAs at the concentration of 1µmol/l (~0.4 µCi) for 40 minutes at 37 °C. 
After washed three times with PBS, the cells were lysed with RIPA buffer and the cell-
associated radioactivity was counted by LSC 6500-multiplepurpose scintillation counter 
(Beckman Counter, Fullerton, CA). For competition assay, 20-fold extra unlabeled GS24-
NFκB was added to the medium 30 min before adding 32P-labeled DNAs.  
4.5 DNA treatments in inflammatory models in vitro 
4.5.1 TNF-α model 
Briefly, the confluent bEnd5 cells were firstly incubated with GS24-NFκB or its 
corresponding controls in serum free medium for 2 hour. Then TNF-α (50 µg/ml) 
(Shenandoah Biotechnology, Warwick, PA, USA) was added to the medium to stimulate 
inflammation of bEen5 cells for 4 hours, and then cell samples were harvested.  
4.5.2 The OGD/R model 
The OGD/R model was used to mimic ischemia/reperfusion in vitro. Briefly, hypoxia 
was induced by placing cells in a sealed chamber (BillupsRothenberg, Del Mar, CA) at 
37 °C, which has been flushed with 95% N2 /5% CO2 gas. The concentration of oxygen 
in the atmosphere was maintained at 0% oxygen and the PO2 in the medium was below 
25 mmHg. Aglycemia was induced by using RPMI 1640 medium (without L-glucose) 
(Hyclone, Logan, UT). After 9 hours OGD, the cells were back to normal growth 
condition for 16 hours. Then the growth medium was changed to serum free medium and 
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the cells were incubated with GS24-NFκB or its corresponding controls for another 8 
hours. The cell samples were obtained at 24 h after reoxygenation.   
4.5.3 Preparation of protein samples 
4.5.3.1 Whole cell lysate 
Cells were sonicated briefly in ice-cold 1X RIPA buffer containing PMSF, sodium 
orthovanadate and protease inhibitor cocktail solution (Santa Cruz Biotechnology, Inc. 
CA). After incubation in ice-cold buffer for 30 minutes, centrifuge tissue/cell lysate at 
10,000xg for 10 minutes at 4°C. The supernatant fluid was harvested for the following 
steps. An appropriate volume of Laemmli sample buffer with 2-mercaptoethanol was 
added to the homogenate, and the samples were incubated in a water bath at 100°C for 8 
min[185].  
4.5.3.2 Nuclear protein extraction 
Cells were washed and lysed in ice cold buffer-A containing 10 mM HEPES pH 7.9, 1.5 
mM MgCl2, 10mM KCl, 0.25% v/v noident P-40, 0.5 mM dithiothreitol (DTT), 0.5 mM 
phenylmethylsulfonyl fluoride (PMSF) in deionised water (dH2O) for 10 min. The 
supernatant cytoplasmic and nuclear pellet fractions were obtained by centrifuging cell 
samples at 12,000g for 2 min. Nuclear protein was extracted from the pellet with the ice 
cold buffer-B containing 20 mM HEPES pH 7.9, 1.5 mM MgCl2, 0.42 M NaCl, 0.5 mM 
DTT, 25% v/v Glycerol, 0.5 mM PMSF in diH2O for 20 min. Then the nuclear fractions 
were collected and diluted in the buffer-C containing 20 mM HEPES pH 7.9, 50 mM 
KCl, 0.5 mM DTT, 0.2 mM EDTA, 0.5 mM PMSF[186]. Finally, the protein 
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concentrations were measured, and western blotting was performed. All the chemicals 
were purchased from Sigma-Aldrich Inc. 
4.5.4 Western blot 
Protein samples were loaded onto SDS-polyacrylamide gels (Bio-Rad, Hercules, CA), 
and ran for 1.5 h at 120 v. The proteins were transferred with a semidry transfer cell (Bio-
Rad) over night at 4°C. After transfer, the membranes were blocked with 5% fat-free 
milk in 10 mM Tris, 100 mM NaCl, and 0.1% Tween 20 (TBST; pH 7.5) for 1 h. The 
membranes were washed three times for 15 min with TBST and incubated with 
corresponding primary antibodies overnight at 4°C, followed by three additional washes 
with TBST for 15 min and incubation with secondary antibody for 1 h. Final detection 
was carried out with enhance chemiluminescence methodology (Pierce Supersignal West 
Dura) and the intensity of the signal was measured with software AlphaEaseFC. Nuclear 
expression of P-65 and expression of ICAM-1 and VCAM-1 were determined. The β-
actin was used as the protein loading control marker for whole cell lysate and TATA 
binding protein (TBP) was used as protein loading control marker for nuclear protein. 
The following antibodies and the respective dilutions were used in western blotting 
procedure: 1: 2,000 (dilution) β-Actin antibody (Cell Signaling Technology, Danvers, 
MA), 1:1,000 ICAM-1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA), 1:2,000 
VCAM-1 antibody and 1:1,000 TBP antibody (Abcam, Cambridge, MA)[185].  
4.5.5 RT-PCR 
Total RNA was extracted using the ready-to-use reagent TRIzol (life technology). 
Briefly, the medium was removed and TRIzol was added to each well and the cells were 
lysed by pipetting the cells up and down several times. After incubation at room 
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temperature for 5 min, the homogenized samples were well mixed with chloroform and 
incubated for another 2 min. Then the samples were centrifuged at 12,000 × g for 15 
minutes at 4°C. The aqueous phase was transferred into a new tube and then 100% 
isopropanol was added into the tube. After 10 min incubation on ice, the samples were 
centrifuged at 12,000 × g for 10 minutes at 4°C. The RNA pellets were washed with 75% 
ethanol and air dried. Nuclease-free water was used to prepare RNA samples for further 
analysis. Then cDNAs were obtained using the RNA as template and high-capacity 
cDNA reverse transcription Kit (life technology) according to manufacturer’s protocol. 
Finally, RNA were quantified by quantitative real-time PCR with two gene specific 
primers and SYBR® Green real-time PCR master mixes (life technology). The following 
forward and reverse primers were used[126]: VCAM-1: 5'-AAG ACT GAA GTT GGC 
TCA CAA-3' and  5'-GGA GTT CGG GCG AAA AAT AG-3'; ICAM-1: 5'-GGG AAT 
GTC ACC AGG AAT GT-3' and 5'-CAG TAC TGG CAC CAG AAT GA-3' ; β-actin: 
5'-GGC TGT ATT CCC CTC CAT CG-3' and  5'-CCA GTT GGT AAC AAT GCC ATG 
T-3'. The mRNA expression of β-actin was used as internal control. All the primers were 
purchased from Integrated DNA Technologies Inc. 
4.5.6 Adhesion assay 
U937 cells (a monocyte cell line from ATCC) were incubated with 5 mg/mL BCECF-
AM (2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester, Sigma Inc.) 
for 30 minutes at 37°C, and then the cells were washed and resuspended in serum free 
media. For ODN treatments in TNF-α stimulated bEND5 cells, bEND5 cells were 
cultured and incubated with ODNs in a 24-well plate for 2 h. Then TNF-α (20ng/ml) was 
added and incubated for 16 h, and then the cells were incubated with BCECF-AM-
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labeled U937 cells (106cells/well) for 30 minutes at 37°C. For ODN treatments in 
OGD/R condition, the bEND5 cells were treated as described early in OGD/R model, and 
then cells were incubated with BCECF-AM-labeled U937 cells (106cells/well) for 30 
minutes at 37°C. Non-adhering U937 cells were removed and cells were washed with 
PBS, then cells were lysed in 0.1% Triton X-100 in 0.1M Tris-HCl (pH7.4) (Sigma-
Aldrich). Fluorescence (F) was measured with a microplate fluorescence reader (POLAR 
star OPTIMA, BMG Labtechnologies, Ortenberg, Germany) using excitation at 492 nm 
and emission at 535 nm. The monocyte adhesion was calculated as: Adhesion (%) 
=100×Fsample/F total (F: fluorescence intensity of 106cells) [126]. 
4.6 Pharmacokinetics and tissue distribution 
Male CD1 mice (body weight ~25g, supplied by Charles River Inc, Wilmington, MA, 
USA) were anaesthetized by injection of Ketamine and Xylazine (Butler Animal Health 
Supply Inc. Dublin, OH, USA). 32P-labeled ODNs (13µg, 100μl, ~2μCi) were 
intravenously administered through jugular vein. Blood samples were obtained by orbital 
puncture at 0, 2, 5, 10, 20, 30, 45 and 60 min. And then mice were sacrificed by 
decapitation and organs including lung, heart, spleen, kidney, liver and brain were 
sampled and weighed. Blood was centrifuged at 2000g and 4°C for 10min, and the 
plasma was collected[187]. The radioactivity of the plasma was measured. One aliquot of 
plasma was treated with TCA precipitation to obtain the TCA-precipitable radioactivity 
[184]. The radioactivity levels in the injected solutions serve as internal standards. The 
plasma concentrations were expressed as percentage of injected dose per µl of plasma at 
the various time points. Concentration-time data were fitted to bioexponential equation 
and analyzed by PKSolver. The organs were cut into pieces and solubilized in 3% KOH 
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at 50°C for 4 h as well as decolorized in 5% H2O2. Radioactivity of all samples was 
measured by LSC 6500-multiplepurpose scintillation counter. DNA accumulations in the 
organs were expressed as percent of injected dose %ID/g. The results were corrected for 
capillary plasma content in organs, 48.2, 170, 140, 114, 83, 9.3 μl/g for heart, lung, liver, 
spleen, kidney and brain respectively. 
4.7 DNA treatment in mouse LPS model 
4.7.1 DNA treatment in LPS model 
Lipopolysaccharide (LPS, Sigma-Aldrich) was dissolved in sterile saline, aliquoted, and 
stored at -20°C until use. LPS model was established by a single intraperitoneal (i.p.) 
injection with 1mg/kg LPS. For measurement of phospho-P65 expression, at 3 h after 
LPS challenge, GS24-NF-κB or its scramble control was administered by intravenous 
(i.v.) injection via jugular vein with the dose of 15mg/kg. Brain samples were obtained 
after 3 h of DNA treatment. Phospho-P65 (Ser536) antibody was purchased from Cell 
Signaling Technology. For analysis of VCAM-1 expression, at 16 h after LPS injection, 
GS24-NFκB or its scramble control was administered by i.v. injection with the dose of 
15mg/kg. Brain samples were collected after 4 h of DNA treatment (Fig.8).  
4.7.2 Brain microvessel isolation 
Brain samples were homogenized in a tissue grinder with ice cold medium 131 (life 
technologies, Grand Island, NY) supplemented with 2% FBS, 1% (v/v) 10,000 IU/ml 
penicillin/10,000 mg/ml streptomycin. The homogenates were suspended in 16% dextran 
(average molecular weight 100,000g, Sigma-Aldrich) and centrifuged at 5000RPM for 20 
min. Then the supernatant containing fatty layer was removed and vascular pellet was 
digested with 0.1% collagenase and 10µg/ml DNase at 37°C for 1 h with occasional 
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agitation. The digested microvessel was filtered through a 70µm nylon mesh cell filter 
and the microvessels were collected with centrifugation at 1000g for 5 min [188]. Then 
the cells were lysed and used for further analysis.  
4.7.3 Sickness behavior analysis 
The mouse was placed individually in a new cage similar in all aspects to the homecage 
and videotaped for 5 min and then moved back to homecage. The recordings were 
analyzed offline by overlapping a grid consisting of 12 identical rectangles (3-by-4 array) 
on the cage floor and counting the number of rectangles the mouse has entered with all 
four paws during the test period. The spontaneous locomotor activity of each mouse was 
tested before LPS injection, at 16 h after LPS injection and at 4 h after DNA treatment 
(Fig.8a). The activity measured before LPS injection was set as baseline and the activity 
following the LPS challenge was expressed as percentage of baseline activity[189]. 
  
(a) (b) 
Figure 8 Experimental time line. 
4.8 Statistical analysis 
Results are expressed as the mean ± S.D. of n experiments. Statistical analysis was 
performed by analysis of variance, followed by posttests (Dunett’s test for comparison of 
experimental groups versus control conditions). A p value of < 0.05 was chosen as the 
threshold of significance. 
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CHAPTER 5 
RESULTS 
 
5.1 Formation of GS24-NFκB complex 
The design and sequence of GS24-NFκB is shown in Fig.9: NF-κB 2 sequence is 
complementary to the NF-κB1 sequence in the 3’ end of GS24-NFκB1 (showed in bold) 
to form GS24-NFκB DNA. The electrophoretic gel Image (Fig.10) indicated that the 
oligonucleotides with different molecular weight exhibited different migration rates.  The 
migration distance of GS24-NFκB is the shortest due to its biggest molecular weight, 
which verified the formation of GS24-NFκB complex. 
 
 
Figure 9 Design and predicted structure of GS24-NFκB complex by M-fold. 
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Figure 10  Formation of GS24-NFκB complex: the ODNs were electrophoresed in 8% 
native-PAGE gel: NF-κB-decoy-1 strand (lane 1), NF-κB-decoy-2 strand (lane 2), NF-κB 
decoy (lane 3), GS24-NFκB-decoy-1 (in lane 4), GS24-NFκB complex (lane 5). 
 
5.2 Targeted delivery of GS24-NFκB into bEnd5 cells 
To evaluate the cellular delivery capability of aptamer GS24, the DNA complex and 
naked NF-κB decoy were labeled with Cy3. Cellular binding and internalization were 
indicated by cell-associated fluorescence signals, which were observed and analyzed by 
FACS. The results in Fig.11, suggested a significant shift for GS24-NF-κB complex but 
no shift for naked NF-κB decoy, which indicated that GS24-NF-κB showed higher 
cellular binding/uptake efficacy but NF-κB decoy without aptamer showed no 
binding/uptake.  
We further investigated the quantitative uptake of the DNA complex and the delivery 
specificity. DNAs were 5’-end labeled with [γ-32P] ATP and cell-associated radioactivity 
represented the cellular binding and internalization. The radioactivity for GS24-NFκB 
treatment was 42491±11668 (mean±SD) CPM while it was 6220±3621 CPM for 
scramble control, which suggested that cellular uptake of GS24-NF-κB was much higher 
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(5.8 fold) than that of scramble control. The results of competition assay indicated that in 
the presence of extra unlabeled DNA complex, the delivery of GS24-NFκB into bEnd5 
cells was reduced by 90% with radioactivity of 388±49 CPM (Fig.12a). Anti-TfR siRNA 
was transfected into bEnd5 to block the expression of TfR, which was verified by 
western blot (Fig.12b). The uptake of GS24-NF-κB in normal bEnd5 cells was 3.6±0.7 
times of that in the TfR silencing cells (Fig.12b).  
 
Figure 11  Flow cytometry detection: cellular uptake of GS24-NFκB complex 
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(a)                                                              (b) 
Figure 12 (a) Quantitative uptake of GS24-NFκB in bEnd5 cells, Mean ± SD, n = 6-8, 
**p < 0.01. (b) Representative western blotting image of TfR expression after siRNA 
silencing in bEND5 cells and cellular uptake of GS24-NFκB in TfR+/- cells. Mean ± SD, 
n = 3, P<0.05.  
 
5.3 Pharmacological effect of GS24-NFκB in vitro  
5.3.1 GS24-NFκB reduced nuclear P65 expression in OGD/R and TNF-α 
inflammatory models 
P65 is an important subunit of NF-κB. bEnd5 cells  stimulated by TNF-α or subject to 
OGD/R were treated with DNAs and then nuclear proteins were extracted and nuclear 
P65 levels were measured. In OGD/R model, nuclear P65 level was increased to 
1.95±0.13 times of the untreated control after OGD/R.  But the increase was obviously 
reversed by DNA treatments in a dose dependent manner. The nuclear P65 levels were 
136± 20, 136± 14, and 99 ± 20% of untreated control in GS24-NFκB treatment groups at 
concentrations of 2, 4, and 8 µM respectively. The scramble control did not significantly 
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affect the nuclear P65 level, which were 184±26, 182±14, and 165±23% of untreated 
control at concentrations of 2, 4, and 8 µM respectively (Fig.13). TNF-α, as an 
inflammation factor, also enhanced expression of nuclear P65, which was 204±38% of 
control after TNF-α stimulation.  But the levels were reduced to 133±21% with DNA 
treatment at a concentration of 2 µM. At the same concentration, naked NF-κB decoy and 
scramble control had no significant effect on the nuclear P65 levels, which were 215±52 
and 181±26% relative to untreated control (Fig.14). 
 
(a) 
 
(b) 
Figure 13 (a) Representative image of western blotting in P65 expression in nucleus in 
OGD/R model. (b) Effect of GS24-NF-κB on the nuclear level of P65 in OGD/R model, 
Mean ± SD, n = 3, ###P < 0.001 vs untreated control, *P< 0.05 vs corresponding scramble 
controls. 
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(a) 
 
(b) 
Figure 14  (a) the representative image of western blotting in P65 expression in nucleus in 
TNF-α model. (b) Effect of GS24-NFκB (2μM) on the nuclear level of P65 in TNF-α 
model, Mean ± SD, n = 3-5, ##P < 0.01 vs untreated control, *P< 0.05 vs scramble 
control, ***P< 0.001 vs NF-κB decoy treatment. 
5.3.2 GS24-NFκB inhibited VCAM-1 expression in OGD/R and TNF-α 
inflammatory models 
We investigated the expression of NF-κB-dependent inflammatory gene VCAM-1. Under 
OGD/R condition, VCAM-1 expression was significantly enhanced, which was 383±19% 
of untreated control. However, the expressions were reduced to 278±79, 259±41, 
209±15% of control in DNA treatment groups at concentrations of 2, 4, 8 µM 
respectively. But the scramble control did not result in any decrease in the VCAM-1 
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expression, which were 349±24, 360±38 and 393±24% at concentrations of 2, 4, 8 µM 
respectively (Fig.15). In TNF-α model, VCAM-1 level was dramatically increased. Since 
the signal for media control group was very weak, it is difficult to quantify the 
expression. In this case, TNF-α group was used as control group and the results of other 
groups were all normalized to that of TNF-α group. GS24-NFκB significantly reduced 
the VCAM-1 expression at a concentration of 2 µM, which was 67±8% of TNF-α 
control. Scramble ODN had no significant pharmacological effect with VCAM-1 level of 
87±11% of control. In addition to protein expression, mRNA expression of VCAM-1 was 
also examed. TNF-α dramatically upregulated the mRNA level of VCAM-1, about 19 
times of media control. As expected, GS24-NFκB significantly decreased the mRNA 
expression to 9±2 times of media control. But the scramble GS24-NFκB did not change 
the VCAM-1 expression, which was 18±5 times of media control（Fig.16） 
 
 
 
 
. 
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(a) 
 
(b) 
Figure 15 (a) Representative image of western blotting in VCAM-1 expression in OGD/R 
model. (b) Effect of GS24-NF-κB on the VCAM-1 expression in OGD/R model, Mean ± 
SD, n = 3, ###P < 0.001 vs untreated control, *P< 0.05, ***P< 0.001 vs corresponding 
scramble controls. 
 
(a) 
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(c) 
Figure 16  (a) Representative image of western blotting in VCAM-1 expression in TNF-α 
model. (b) Effect of GS24-NFκB (2μM) on the VCAM-1 expression in TNF-α model, 
Mean ± SD, n = 3-6, **P < 0.01 vs NF-κB decoy treatment and scramble control.(c) 
Effect of GS24-NFκB (2μM) on the mRNA expression of VCAM-1 in TNF-α model, 
Mean ± SD, n = 3, ##P < 0.01 vs media control, *P <0.05 vs scramble control. 
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5.3.3 GS24-NFκB inhibited ICAM-1 expression in TNF-α model 
ICAM-1 is another NF-κB-dependent inflammatory molecule and the effect of GS24-
NFκB on the ICAM-1 expression in TNF-α model was investigated. The results 
suggested that GS24-NFκB significantly mitigated the upregualtion of ICAM-1 
expression induced by TNF-α. The ICAM-1 level stimulated by TNF-α was 173±23% of 
media control but the level was decreased to 122±21% of media control by GS24-NFκB 
treatment at a concentration of 2µM. Negative controls including scramble GS24-NFκB 
and naked NF-κB decoy did not affect the expression of ICAM-1, in which the ICAM-1 
expression were 190±32 and 200±42% of control respectively. RT-PCR results showed 
similar mRNA expression profile of ICAM-1. TNF-α enhanced the mRNA level of 
ICAM-1, which was 29±5 fold of control. In DNA treatment group, mRNA expression 
was only 17±3 fold of control. Scramble ODN and naked NF-κB decoy did not result in 
any significant change in ICAM-1 transcript (Fig.17). 
 
(a) 
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(b) 
 
(c) 
Figure 17 (a) Representative image of western blotting in ICAM-1 expression in TNF-α 
model. (b) Effect of GS24-NFκB (2μM) on the ICAM-1 expression in TNF-α model, 
Mean ± SD, n = 3-8, ##P < 0.01 vs media control, **P < 0.01 vs NF-κB or scramble 
control. (c)  Effect of GS24-NFκB   (2μM) on the mRNA expression of ICAM-1 in TNF-
α model, Mean ± SD, n = 3-4, ###P < 0.001 vs media control, **P < 0.01 vs NF-κB decoy 
or scramble control. 
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5.3.4 GS24-NFκB inhibited monocyte adhesion to bEND5 cells in TNF-α and 
OGD/R inflammatory models 
In addition to expression of adhesion molecules, the effect of GS24-NFκB on the 
monocyte adhesion was investigated by U937 adhesion assay. When endothelial cells 
were stimulated by TNF-α, the percentage of monocyte adhesion to brain endothelium 
was increased to 11.3±0.6% compared to non-activated endothelial cells with 6.1±0.6%   
adherent monocytes. GS24-NFκB at concentrations of 2 and 4µM reduced the percentage 
of adherent U937 cells to 7.7±0.6 and 7.5±0.9% respectively. To exclude any nonspecific 
inhibition in adhesion, the experiments were done with scramble GS24-NFκB at 
concentrations of 2 and 4 µM, which did not result in significant decrease in adherent 
U937 cell with percentage of 11.5±0.7 and 10.5±0.2% respectively (Fig.18a). The 
percentage of adherent U937 cells was 5.1±0.2% but the number was significantly 
promoted to 9.9±1.1% under OGD/R condition. U937 adhesion was decreased to 
5.9±0.6, 6.7±0.5 and 3.9±0.2% with GS24-NFκB treatments at concentrations of 2, 4, 8 
µM respectively. Scramble controls at same concentrations did not significantly alter the 
U937 adhesion, which were 10.3±0.9, 11.9±0.5 and 9.6±0.8% respectively (Fig.19a). The 
representative images were presented in the Fig.18b and Fig.19b. 
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(a) 
 
(b) 
Figure 18 (a) Effect of GS24-NFκB on monocytes adhesion to bEND5 cells in TNF-α 
model, Mean ± SD, n = 3, ###P < 0.001 vs media control, ***P < 0.001 vs corresponding 
scramble controls.(b) Representative images for adhesion assay in TNF-α model (A: 
media control; B:TNF-α; C: TNF-α + scramble control(4μM); D: TNF-α + GS24-NFκB 
(2μM); E: TNF-α + GS24-NFκB (4μM)). 
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(a) 
 
(b) 
Figure 19 (a) Effect of GS24-NFκB on monocytes adhesion to bEND5 cells in OGD/R 
model, Mean ± SD, n = 3, ###P < 0.001 vs media control, ***P < 0.001 vs corresponding 
scramble controls.(b) Representative images for adhesion assay in OGD/R model (A: 
media control; B:OGD/R; C: OGD/R + scramble control(4μM); D: OGD/R + GS24-
NFκB (2μM); E: OGD/R + GS24-NFκB (4μM); F: OGD/R + GS24-NFκB(8μM)). 
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5.4 Pharmacokinetics and organ distribution 
The plasma concentration-time profiles for total radioactivity and TCA-precipitable 
radioactivity following intravenous injection of GS24-NFκB were shown in Fig.20a. The 
plasma concentration-time profiles for TCA-precipitable radioactivity after intravenous 
injection of GS24-NFκB and scramble control were shown in Fig.20b. Both plots 
indicated a typical two-phase kinetics with an initial rapid distribution phase, followed by 
a relatively slow elimination phase. At each time point, the TCA-precipitable 
radioactivity was always lower than the total radioactivity and the concentration of GS24-
NFκB was always higher than that of the scramble control. The key pharmacokinetic 
parameters were listed in table 1, which indicated very short half-life time 1.92 min and 
clearance with 0.35 ml/min. 
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(b) 
Figure 20  Plasma concentration time profiles: (a) GS24-NFκB and TCA-precipitable 
GS24-NFκB; (b) GS24-NFκB and scramble GS24-NFκB 
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Table 1 Key pharmacokinetic parameters: (a) GS24-NFκB; (b) scramble GS24-NFκB 
(a) 
Key parameters  Unit  Mean(SD) 
t1/2,α min 1.92(0.16) 
t1/2,β min 88.9(43.7) 
V ml 1.46(0.10) 
Cl ml/min 0.353(0.054) 
AUC_60 (%ID/ml)*min 222(15) 
 
(b) 
Key parameters  Unit  Mean(SD) 
t1/2,α min 0.79(0.24) 
t1/2,β min 21.9(23.8) 
V ml 2.07(0.37) 
Cl ml/min 1.24(0.15) 
AUC_60 (%ID/ml)*min 76(2.3) 
 
The organ distribution for both DNA complex and scramble control groups was indicated 
in Fig.21. The brain accumulations for both groups were shown in Fig.21b. In all the 
organs, distribution of GS24-NFκB was much higher compared to the scramble control. 
The organ accumulations of GS24-NFκB were 7.7, 4.2, 11.1, 9.7, 13.4, 0.39%ID/g for 
heart, lung, liver, spleen, kidney and brain respectively. 
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(a) 
 
(b) 
 
Figure 21  Organ distribution of GS24-NFκB and scramble control: (a) heart, lung, 
spleen, liver, kidney and brain; (b) brain, Mean ± SD, n = 3, **P < 0.01 vs scramble 
control. 
 
5.5 GS24-NFκB inhibited P65 activation and VCAM-1 expression in mouse LPS 
model 
LPS, a potent inducer of inflammation, was used to produce neuroinflammation within 
the brain in the present study. Since the target of the ODN-based delivery system is brain 
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endothelial cells, brain microvessel fraction was isolated and used for protein analysis. 
The expressions of phospho-P65 (an important indicator for NF-κB activation) and 
VCAM-1 were measured. LPS administration increased the level of phospho-P65 and 
VCAM-1 (data did not show here). However, GS24-NFκB had effect on reducing the 
phospho-P65 expression (141±26% of media control) compared to that of scramble ODN 
(201±34% of media control) (Fig.22). In addition, VCAM-1 expression in scramble 
control group was 218±39% of media control while the level was significantly decreased 
to 142±29 %of control (Fig.23). The spontaneous locomotor activity significantly 
dropped to about 50% of baseline at 16 h following the injection of LPS. However, the 
systemic administration of GS24-NFκB and scramble control did not relieve the 
suppression of locomotor activity (Fig.24). 
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(b) 
Figure 22 (a) Representative image of western blotting in phospho-P65 expression in 
mouse LPS model.(b) Effect of GS24-NFκB (15mg/kg) on the phospho-P65 level in 
mouse LPS model, Mean ± SD, n = 5-6, ###P < 0.001 vs media control, **P < 0.01 vs 
scramble control. 
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(b) 
Figure 23 (a) Representative image of western blotting in VCAM-1 expression in mouse 
LPS model.(b) Effect of GS24-NFκB (15mg/kg) on the VCAM-1 level in mouse LPS 
model, Mean ± SD, n = 4-5, ###P < 0.001 vs media control, *P < 0.05 vs scramble 
control. 
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Figure 24 Effects of DNA complex on sickness behavior induced by systemic 
administration of LPS, Mean ± SD, n = 4, **P < 0.01, *P < 0.05 vs baseline 
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CHAPTER 6 
DISCUSSION AND CONCLUSION 
 
6.1 The complexity of the role of NF-κB in CNS 
Transcription factor NF-κB is a key regulator of a huge array of genes involved in cell 
survival and inflammation. It does not only participate in the regulation of physiological 
functions in CNS, including neuroprotection in neural development, synaptic 
transmission, spatial memory formation and neuroplasticity [190-192], but also act in 
stressed or pathological conditions, including cerebral ischemia, multiple sclerosis and 
neurodegenerative diseases. Unfortunately, the role of NF-κB in CNS pathologies is not 
clear as NF-kB may exert a dual role: protective or detrimental. The “double life” of NF-
κB may challenge our application of NF-κB decoy in CNS diseases to treat 
neuroinflammation. Therefore, it is important to discuss the role of NF-κB in CNS first to 
justify the therapeutic application in the study.  
In cerebral ischemia, many experiments have firmly established that NF-κB is activated 
in neurons, endothelial cells, astrocytes and microglia, indicated by its nuclear 
translocation, increased DNA binding and transcriptional activity. To elucidate the 
function of NF-κB, a range of mouse genetic strategies have been used. The infarct size 
was significantly reduced in both transient and permanent stroke models in p50-knockout 
mice [193, 194]. Introduction of mutation at the phosphorylation sites of IKK also 
suppressed NF-κB activation and thus decreased infarct size and improved neurological 
outcome[195].In addition, NF-κB inhibitors such as antioxidants or NBD also showed 
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neuroprotective effects. NF-κB activity was markedly inhibited by pre-treatment with 
antioxidants pyrrolidine dithiocarbamate (PDTC) and N-acetylcysteine (NAC) in the rat 
cerebral ischemic model. The two antioxidants also promoted cell survival and reduced 
neuronal loss in rat hippocampus [196]. NBD with the function of inhibiting IKK and 
block NF-κB activation significantly suppressed the activation of microglia and 
ameliorated the disruption of BBB, which suggested the inflammation was inhibited. 
Moreover, the treatment improved the neurological scores and reduced cell apoptosis in 
rat cerebral ischemia-reperfusion injury [197]. All of the above studies supported that 
NF-κB plays a detrimental role in cerebral ischemia. However, controversial reports 
indicated that NF-κB contributes to the neuroprotective effect. Duckworth et al. found 
that in hippocampus in mouse ischemic brain, neurodegeneration in p50-deficiency mice 
was about 8 fold increase relative to non-transgenic mice. And the neurodegeneration 
was only confined to the areas with low NF-κB activity[198]. It is well-known that 
preconditioning confers resistance to neurons against a subsequent, prolonged ischemia. 
And this neuroprotection depended on the activation of NF-κB in neurons in 
preconditioning. Inhibition of NF-κB activation at the time of the preconditioning 
abolished the protective effect [199]. 
In conclusion, the role of the NF-κB in CNS pathologies is dependent on context, 
including cell types, kinetics of NF-κB activation, insults, combinations of the NF-κB 
dimer and interaction with other signaling cascades. The kinetics (timing and duration) of 
NF-κB inhibition is critical in determining outcome. As mentioned above, the activation 
of NF-κB in preconditioning ischemia was neuroprotective while it was toxic in manifest 
ischemia. One explanation is that transient activation induced expression of anti-
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apoptotic genes but prolonged activation promoted apoptotic and inflammatory genes, 
which is consistent with the experiment results obtained by Nijboer et al[200]. They 
inhibited NF-κB with NBD coupled to the protein transduction sequence of HIV-TAT 
(TAT-NBD) to facilitate cerebral uptake in neonatal hypoxic-ischemic model at different 
times and with different duration. Prolonged treatment increased the pro-apoptotic factors 
and reduced the anti-apoptotic proteins. In addition, they found out that early NF-κB 
activation contributes to the brain damage while late activation protected neurons by up-
regulating anti-apoptotic molecules.  
Moreover, NF-κB regulates the patterns of induced genes in a cell-type-specific manner. 
NF-κB was found to be constitutively active at high basal levels in neurons and the 
constitutive NF-κB activation was required for neuron survival. Inhibition of endogenous 
neuronal NF-κB activity in cortical neurons contributed to neuronal death while induction 
of NF-κB via overexpression effectively protected primary cortical neurons from death 
[201]. Emmanouil et al. generated neuronal IKKβ-deficient mice in MS model, which 
showed reduced CNS production of neuroprotective factors and increased production of 
proinflammatory cytokines and chemokines. This results supported that neuronal NF-κB 
activation is essential to neuroprotection and suppression of inflammation [202]. In 
contrast to neurons, no constitutive NF-κB activity is observed in glial cells in normal 
condition, which may indicated the different role in these cells. Astrocyte-specific 
inhibition of NF-κB protected mice in MS model as expressions of proinflammatory 
cytokines and chemokines were suppressed and the expressions of neuroprotective 
factors were promoted [203]. On the other hand, a constitutive expression of IKK in 
astrocytes induced a widespread neuroinflammation, indicated by the increased 
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expression of inflammatory cytokines and the presence of activated microglia and 
astrogliosis [110]. Inhibition of NF-κB by knockout of IKK in microglia significantly 
reduced the infarct size in kainic acid challenged mice by decreasing the expression of 
inflammatory mediators, such as TNF-α and IL-1β, which indicated activation of NF-κB 
contributes to excitotoxin-induced neuronal cell death[204]. Endothelial cell-specific NF-
kB inhibition also relieved inflammation by blocking the expression of inflammatory 
molecules [126]. Based on the above previous studies, it is logical to hypothesize that 
activation of neuronal NF-κB may promote survival of neurons by inducing the 
expression of neuronal anti-apoptotic genes, but activation of endothelial or immune NF-
κB is deleterious in ischemic stroke or other neuroinflammatory diseases by inducing the 
synthesis of inflammatory mediators. In the present study, an ODN-based brain drug 
delivery system was developed, which consists of NF-κB decoy and GS24 aptamer for 
targeted delivery of NF-κB decoy into brain endothelial cells. The GS24-NFκB may 
overcome lacking of specificity in NF-κB inhibition and poor efficiency in delivery by 
targeting a disease relevant cell population, the brain endothelial cells. Therefore, the 
refined approach used in the present study will only inhibit deleterious NF-κB in cerebral 
vascular endothelium but leave beneficial NF-κB activity not affected. 
6.2 Formation of GS24-NFκB conjugate 
The GS24-NFκB is a dual functional DNA complex containing a targeting moiety, GS-
24, for transporting the complex by binding to the TfR, and a DNA decoy for inhibiting 
NF-κB activity. As shown in Fig. 4, a completely DNA-based complex has been 
synthesized (lane 5). The aptamer GS24 was covalently connected to the decoy ODN via 
phosphodiester bond. The GS24 was fused with one strand of the decoy as a whole 
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strand, which was subsequently annealed with the other strand of the decoy to form a 
DNA chimera. This resulting linkage promotes the stability of conjugation such that 
decoy release during the transport is prevented before it is localized to its cellular target. 
The completely DNA-based drug delivery system significantly limits the 
immunogenicity. It can be chemically synthesized in large quantities and amenable to 
various chemical modifications for improved serum stability and pharmacokinetics. The 
size of the DNA complex is relatively small, which promotes tissue penetration compared 
to large molecules.  
6.3 Cellular uptake of NF-κB  
Delivery of GS24-NFκB was investigated in bEnd5 cell as it is a useful in vitro model of 
the BBB for drug delivery studies and modeling pathological conditions. A maximal 
transendothelial electrical resistance of 121 Omega cm2 was obtained for bEnd5 
monolayers. The cells expressed tight junction proteins including ZO-1, occludin and 
claudin-1, as well as the transporters P-glycoprotein (P-gp), Na-K-Cl co-transporter 
(NKCC), Glucose transporter 1 (GLUT1), and most protein kinase C (PKC) isoforms. 
The paracellular and transcellular permeability were investigated by marker permeability 
experiments in both normoxia and hypoxia/aglycemia conditions, which indicated that 
bEnd5 cells formed a tight barrier and were sensitive to hypoxia/algycemia treatment 
[205]. Cell surface receptor, TfR, has been proven to be highly expressed on bEnd5 cells 
and the expression was up-regulated in disease conditions [127, 206], which give more 
selectivity for our brain gene delivery system. Flow cytometry results confirmed the 
delivery capability of GS24-NFκB, which suggested that conjugation with NF-κB decoy 
did not affect the conformation and binding ability of GS24. Quantitative uptake of 32P-
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ODNs demonstrated the delivery specificity as cellular uptake of GS24-NFκB was much 
higher relative to scramble control but it was largely reduced in the presence of extra 
unlabeled GS24-NFκB in the competition assay. In order to demonstrate that the delivery 
was indeed mediated by TfR, TfR was silenced in bEnd5 cells by transfection with anti-
TfR siRNA. We found that the binding and internalization of GS24-NFκB was obviously 
decreased in TfR-silenced cells, which indicates that the delivery is not only specific but 
also TfR-dependent.  
Because of the low permeability of BBB, very little macromolecular cargo is 
transcytosed across the cerebral endothelial cells but iron is one of them[207]. TfR has 
been proposed to mediate the transcytosis of iron. In addition to brain endothelial cells, 
TfRs are also found on the surface of neurons and reactive astrocytes [208-210]. Thus 
TfR mediated transcytosis has been explored to deliver therapeutics into brain cells such 
as neurons and astrocytes, which has gained some success [211-213]. With respect to the 
dual role of NF-κB in CNS, we prefer that our DNA conjugate is only internalized into 
brain endothelial cells but not transcytosed into neurons. In the present study, we did not 
investigate the transcytosis of the DNA complex as we hypothesize that it is not able to 
be delivered across the brain endothelial cells. Many studies have provided evidence that 
anti-TfR ligands, especially those with high affinity, were trapped in brain endothelial 
cells [214, 215]. Anti-TfR antibodies, OX26, Ri7 and 8D3, intravenously injected into 
animals were accumulated in brain endothelial cells and not observed in neurons or 
astrocytes. The reasons may be related to the difference of the chemical nature of the 
interaction between TfR and either ligands or transferrin and the difference in the 
tracking pathways mediated by ligands and transferrin [214, 215]. Bien-Ly et al. found 
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that even anti-TfR antibody affinity determined TfR trafficking fate [213]. After 
dissociating from iron, Tf recycled to the plasm while exogenous ligands may not, 
especially for aptamers with poor nuclease resistance in cells. It is supposed unable to 
transcytosed to the other side of cells and therefore the inhibitory effect of NF-κB is 
limited to brain endothelial cells. 
6.4 Pharmacological effect in inflammatory models in vitro 
The central goal of the present study is to target the endothelial NF-κB by this GS24-
NFκB conjugate for inhibition of vascular inflammation. We have used two in vitro 
inflammatory conditions, TNF-α stimulation and OGD/R conditions. TNF-α, an 
endogenous cytokine, is able to induce inflammation and NF-κB activation once binding 
to its receptor, which has been widely used as in vitro inflammatory model due to the 
widespread expression of TNF receptors. OGD/R, modeling hypoxia/reperfusion 
ischemic stroke model in vivo, was used as another inflammatory model as the 
reperfusion injury significantly induces the activation of NF-κB and promotes the 
expression of inflammatory molecules and adhesion molecules[216]. Although NF-κB 
has five subunits, the prototypical form is a heterodimer containing binding subunit, P50 
and trans-activation subunit, P65[55]. Data from cultured endothelial cells indicate that 
P50 and P65 are the predominant species found in nucleus upon cytokine activation [101, 
102]. To evaluate the activation of NF-κB, nuclear P65 level was measured as nuclear 
localization is a key step in NF-κB activation. In both inflammatory models, GS24-NFκB 
chimera significantly reversed the up-regulation of nuclear P65 induced by inflammatory 
stimuli, suggesting that the NF-κB activation was suppressed by the treatment of the 
DNA complex. To further investigate the transcriptional activity of NF-κB, the protein 
69 
 
and mRNA level of NF-κB targeted genes ICAM-1 and VCAM-1 were examed. As 
expected, under inflammatory models (TNF-α and OGD/R), mRNA and protein 
expressions of both molecules were significantly increased. GS24-NFκB successfully 
mitigated the up-regulation and even restored the expressions back to normal level with 
high concentrations. This results were consistent with previous studies, which found that 
NF-κB decoy have effectively decreased the expression of IL-1α, IL-1β, IL-6, ICAM-1, 
and VCAM- 1 at both the transcriptional and translational levels [35, 40, 217]. Since 
adhesion molecules are critical in BBB inflammation by mediating leukocytes adhesion 
and migration, monocyte (U937) adhesion assay was performed to further verify the anti-
inflammatory effect of the DNA complex. GS24-NFκB inhibited monocyte adhesion to 
brain endothelial cells induced by TNFα and OGD/R, which demonstrated that the effect 
of the DNA complex at the protein level has been translated into effects at functional 
level. The significance of this finding is that GS24-NFκB could be potentially used for 
ischemic stroke or other neuroinflammatory diseases therapy. 
Although all the above results strongly supported that GS24-NFκB can be effectively 
delivered into brain endothelium and inhibit activation and transcriptional activity of NF-
κB, there are several issues needed to be addressed. The first concern is the trafficking 
pathway of the DNA conjugate. How did it escaped from the endosomes or lysosomes? 
How was it released from the complex? Theoretically, nucleic acids should be degraded 
very fast in endosomes or lysosomes with low PH and various nucleases. However, a 
number of studies found that aptamer-mediated gene therapy successfully induced 
pharmacological effect in specific cells, which implied that they successfully escaped 
from endosomes or lysosomes [53, 54, 218]. Unfortunately, the intracellular trafficking 
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path and mechanism of endosomal/lysosomal escape are not clear, which need to be 
elucidated in future studies. With respect to the decoy release, there are two possible 
explanation. Nucleases randomly cleaved the DNA sequence but some NF-κB decoy 
ODNs survived and escaped to induce pharmacological effect. Another possible 
mechanism is that the decoy was not released from conjugate and GS24-NFκB as a whole 
complex interacted with NF-κB to inhibit its transcriptional activity. The second concern 
is about the subcellular localization of the NF-κB-bond decoy: cytoplasm or nucleus. 
Generally, molecular weight below 40-60kD is able to pass nuclear pore complex (NPC). 
GS24-NFκB with MW of 29.7kD should be allowed to enter nucleus, which is consistent 
with our observation in confocal microscope that the DNA complex localized both in 
cytoplasm and nucleus (data were not shown here). Previous studies found that delivered 
NF-κB decoy predominantly resided in cytoplasm instead of nucleus in airway epithelial 
cells while other studies indicated that NF-κB decoy was successfully transfected into 
nucleus of hella cells, tracheal epithelial cells (CFTE) and green monkey kidney cells 
(Cos 7)[219-221]. The conflictive results suggest that the nucleic uptake of NF-κB is cell 
type-specific. Moreover, these studies indicated that the cytoplasmic decoy failed to 
inhibit nuclear translocation and transcriptional activity of NF-κB but the nuclear decoy 
successfully blocked the NF-κB activation [219-222]. Based on the studies, we 
hypothesize that there may be three possible mechanisms underlying the reduced nuclear 
level of P65 observed in our study.(1) NF-κB decoy may interact with NF-κB in 
cytoplasm and inhibit its nuclear translocation (Fig.3). Although this hypothesis is not 
consistent with previous studies indicating that cytoplasmic decoy was not sufficient to 
block NF-κB nuclear translocation, the possibility cannot be excluded as even in studies 
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with successful nuclear delivery and NF-κB inhibition, the decoy in nucleus was less than 
20% and most of the decoy (more than 80%) was located in cytoplasm[221]. (2) NF-κB 
decoys may bind to NF-κB in cytoplasm and then the complex is translocated into 
nucleus together. In nucleus, decoy-bound NF-κB cannot interact with target DNA and is 
degraded or exported to cytoplasm. (3) NF-κB decoy may enter nucleus and bind to NF-
κB in nucleus, which may induce NF-κB degradation or export to cytoplasm, resulting in 
decreased nuclear NF-κB level.  
6.5 Pharmacokinetics and biodistribution 
To investigate the behavior of the DNA complex in vivo after intravenous administration, 
the pharmacokinetic profile and organ distribution were evaluated. The plasma 
concentration-time profile showed an expected two-phase kinetics with rapid distribution 
phase (t1/2,α, 1.92 min )and slow elimination phase (t1/2,β, 88.9 min). The DNA chimera 
was rapidly removed from plasma compartment as about 90% of the injected dose was 
removed in the first 5 minutes. The result was consistent with previous studies. The initial 
half-life of a biotin-linked oligonucleotide was 1.5 min [184]. In another study NF-κB 
decoy was conjugated to PEI/PEG polymers and the half-life of the decoy varied from 
1.5 min to 6.5 min[187]. Two key factors may contribute to the rapid removal from 
plasma: nuclease-degradation and renal clearance [223]. On the one hand, GS24-NFκB 
was rapidly degraded by nucleases based on the % TCA precipitability of plasma [32P] 
radioactivity shown in Fig.20a. Total 32P-radioactivity includes both intact and degraded 
oligonucleotides while TCA-precipitable radioactivity represents the real plasma 
concentration since only TCA-insoluble fraction correlates with undegraded and 
minimally degraded ODNs. On the other hand, ODNs was largely cleared by renal 
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infiltration due to their water-soluble properties and the relatively small size (~ 30KD) 
[224] and by tubular excretion because of  the negative charges on GS24-NFκB inducing 
electrostatic clearance across the tubular capillary [225].  
As shown in Fig.20 (a), the clearance rate of total samples including degraded and intact 
ODNs was lower than that of intact ODNs, which is not consistent with our expectation. 
Theoretically, degraded DNAs should show higher clearance rate as their smaller sizes 
facilitate the renal clearance. It is hypothesized that the slower clearance rate of the 
degraded ODNs results from their binding to plasm protein because binding to plasma 
proteins likely prevents glomerular filtration of the oligonucleotides[226]. The hypothesis 
is supported by previous studies, which verified the protein binding capability of ODNs 
and indicated that the protein binding properties are critical to their distribution and 
ultimately the elimination kinetics[226, 227]. 
Compared to the pharmacokinetic parameters of GS24-NFκB, the scramble control had 
reduced the initial half-life (0.79 min), faster clearance and smaller AUC, which may 
result from the absence of three-dimensional structure of the scramble control. The 
scramble control was designed with the same nucleotide composition but different 
sequence. The aptamer has certain folding to facilitate binding to receptor while the 
scramble control did not have, which indicated by the electrophoretic gel image of native-
page gel (data were not shown here). The native gel can maintain the secondary structure 
and native charge density of the nucleic acids. Although they possess the same molecular 
weight, the scramble control migrated faster than GS24-NFκB due to absence of the 
folding. GS24-NFκB may have better serum stability as the three-dimensional structure 
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may mask some cleavage-sites of nuclease[228], which may contributes to the longer 
half-life and higher AUC value relative to the scramble control. 
The highest distribution of GS24-NFκB is in kidney. KANG et al. also reported that 
kidney was the organ with highest accumulation with unconjugated ODNs as it was the 
principal organ responsible for rapid removal of ODN from plasma. High uptake of 
GS24-NFκB was observed in liver and spleen, which was consistent with the organ 
distribution of anti-TfR antibody, OX26. The reason contributing to the high uptake may 
be the high expression of TfR on the liver and spleen. For all the organs, the uptake of 
GS24-NFκB was much higher than that of scramble control, which may results from 
specific uptake mediated by TfR and better pharmacokinetic profiles of GS24-NFκB. 
Since TfR was widely expressed on almost all the organs, GS24-NFκB could be 
specifically taken up by organs via TfR-mediated internalization. The lower clearance 
rate and higher AUC of GS24-NFκB relative to the scramble control may be another 
reason as organ distribution is directly proportional to the plasma AUC and inversely 
related to the rate of plasma clearance[229]. 
Brain uptake of the DNA chimera was 0.39%ID/g, which was much lower relative to 
peripheral organs as expected. To determine whether the brain uptake is high or low, 
comparison between the DNA complex and other molecules for brain delivery was made 
[230] (Table 2). The brain uptake of GS24-NFκB is comparable to that of another TfR 
ligand (0.44%ID/g), OX26, which is anti-TfR monoclonal antibody[229]. OX26 
successfully delivered neuroprotective factors into brain and induced neuroprotective 
effect [231, 232]. Diazepam is a lipid-soluble small molecule that is nearly 100% 
extracted by brain during a single pass through the brain and has no significant efflux 
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[233]. The brain uptake of diazepam in rat is 0.81% ID/g[229], about two folds of that of 
GS24-NFκB. The brain uptake of morphine, another small-molecule drug with less lipid 
solubility as compared to diazepam, is 0.08% ID/g[234]. However, morphine is a 
substrate of P-glycoprotein-mediated efflux system [235, 236]. The brain concentration 
was increased by 3 fold in rats treated with P-gp inhibitor [237]. Therefore, the brain 
uptake of morphine is about 0.24% without efflux, much less than that of GS24-NFκB. 
These comparisons indicate that the brain uptake of GS24-NFκB is acceptable and in the 
range that is expected to induce pharmacological effects in CNS following systemic 
administration. Not surprisingly, higher brain uptake can be obtained using anti-TfR 
antibody. The brain uptake of two anti-TfR monoclonal antibodies 8D3 and RI7-217 
were 3.1 and 1.6%ID/g respectively[238]. The higher uptake may result from longer half-
life, lower clearance and enhanced AUC (Table 3) as the brain uptake is directly 
proportional to the plasma AUC and inversely related to the rate of plasma 
clearance[229]. It is promising that the brain uptake of GS24-NFκB can be further 
increased after improving the pharmacokinetics. 
Table 2 Brain uptake of GS24-NFκB verus small molecules and TfRMAb 
Drug Brain uptake（%ID/g) Animal model 
GS24-NFκB  0.39±0.05 mouse 
OX26 TfRMAb 0.44±0.07 rat 
Diazepan 0.81±0.03 rat 
Morphine 0.08±0.007 rat 
8D3 TfRMAb 3.1±0.4 mouse 
R17 TfRMAb 1.6±0.2 mouse 
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Table 3 Pharmacokinetic parameters for GS24-NFκB and TfRMAbs, 8D3 and R17 
Key parameters GS24-NFκB 8D3 R17 
t1/2(min) 1.92±0.16 363±26 69±4 
Cl(ml/min/kg) 14.12±2.16 0.24±0.03 1.4±0.1 
AUC(t)(%ID*min/ml) 222±15 2059±117 1245±133 
 
6.6 Pharmacological effect in vivo 
LPS, a major component of the Gram-negative bacteria cell wall, is a potent inducer of 
inflammation and now commonly used to produce neuroinflammation as a model for 
neurodegenerative diseases [189, 239]. LPS can be recognized by toll-like receptor 
(TLR).  After binding to TLR, LPS is able to activate NF-κB, resulting in up-regulation 
of proinflammatory cytokines[240]. Systemic administration of LPS firstly induced rapid 
inflammation in peripheral cavity by triggering release of proinflammatory cytokines, 
such as TNF-α, IL-a and inducible isoform of nitric oxide synthase (iNOS) [241, 242]. 
These cytokines can be transported across BBB and activate microglia and endothelial 
cells, leading to inflammatory responses in brain and reduced locomotor activity [243-
246]. 
 In current study, systemic administration of LPS (1mg/kg, i.p) was performed to 
generate neuroinflammatory model to evaluate the therapeutic effect of GS24-NFκB. As 
expected, LPS suppressed the spontaneous locomotor activity to about 50% of the 
baseline. Then the activation of NF-κB and the expression of its targeted gene VCAM-1 
were investigated. Although nuclear translocation of NF-κB is critical for its activation, 
recent evidence suggested that it was not sufficient to activate NF-κB-dependent 
transcription. Phosphorylation of P65 is involved in eliciting a maximal NF-κB response 
[109, 247]. Yang et al. found that LPS induced phosphorylation of the P65 on serine 536 
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and the phospho-P65 (p-P65) effectively enhanced transcriptional activity [247]. 
Consistent with the previous findings, systemic administration of LPS effectively 
increased the level of p-P65 (Ser536) and VCAM-1 in brain microvessel. It is well-
known that the therapeutic use of ODNs is strongly limited by two problems. One is cell 
delivery since the macromolecular, polyanionic and highly hydrophilic nature of ODNs 
hampers their cellular uptake. In the present study, GS24 aptamer successfully solved this 
problem by taking advantage of receptor-mediated transport system on cell surface to 
facilitate cell-specific delivery. The other problem is the pharmacokinetics of ODNs with 
poor serum stability and rapid clearance. However, to our surprise, the inhibitory effects 
of systemic administration of GS24-NFκB on the expression of phospho-P65 and 
VCAM-1 were observed in LPS-challenged mice while the therapeutic effect in behavior 
test was not observed. We hypothesized that most of the administered GS24-NFκB was 
degraded or cleared in circulation and only a little amount finally reached its target, brain 
endothelium. Therefore, with high dose injected, the pharmacological effect on the 
protein expression can be detected in microvessel but the amount is not sufficient to 
induce disease-modifying effect. These results suggest that this novel ODN delivery 
system is promising in the clinical application of treating neuroinflammation once 
pharmacokinetics is improved. 
6.7 Conclusion 
In conclusion, the present study has synthesized an aptamer-therapeutic ODN conjugate 
(GS24-NFκB) for brain delivery of NF-κB decoy with the goal to inhibit 
neuroinflammation. The DNA complex was specifically taken up by bEnd5 cells via 
TfR-mediated endocytosis. In TNF-α and OGD/R induced inflammatory model in vitro, 
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GS24-NFκB significantly reduced nuclear level of P65, indicating inhibition of NF-κB 
activation. The transcriptional activity of NF-κB was effectively suppressed by GS24-
NFκB, indicated by decreased expression of NF-κB-dependent inflammatory genes, 
ICAM-1 and VCAM-1. Moreover, the DNA complex largely inhibited the monocyte 
adhesion to brain endothelial cells induced by TNF-α or OGD/R, which verified anti-
inflammatory effect of GS24-NFκB. Pharmacokinetic study suggested that the DNA 
complex was susceptible to nucleases and removed rapidly from plasma with short half-
life. The DNA complex can be specifically taken up by TfR-expressing cells as high 
distribution was observed in TfR highly expressed organs, spleen and liver. The 
accumulation of GS24-NFκB in brain was about 0.4%ID/g, which was significantly 
higher than that of scramble control. The brain uptake value is high enough to elicit 
pharmacological effects in CNS, which was supported by our in vivo study. GS24-NFκB 
significantly reversed the up-regulation of p-P65 and VCAM-1 in mouse microvessels 
induced by LPS. This study provides a proof of concept for brain-targeted drug delivery 
and a refined approach to target and modulate a particular cell population, the brain 
endothelial cells, relevant to the disease. The study explores the cerebral endothelial cell 
as a novel site of action for brain drug delivery and neuro-vascular inflammation therapy.  
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CHAPTER 7 
FUTURE DIRECTIONS 
 
As a proof of concept study, we have demonstrated the potential of GS24-NFκB in brain 
delivery and inhibition of neuro-vascular inflammation. However, there is a long way for 
clinical application. Future work will focus on the issues mentioned in the discussion 
section, including subcellular localization of the decoy, intracellular trafficking pathway 
and improvement of pharmacokinetics and therapeutic effects in vivo. 
7.1 Intracellular trafficking path and subcellular localization of GS24-NFκB 
Although GS24-NFκB indeed induced pharmacological effect in cells, two questions are 
needed to be answered for verification of its effect. First, although transcription factor 
decoys have been widely used in intervention of many diseases and its potential 
therapeutic application has been proven [35, 40, 127], the mechanisms underlying how it 
works in cells have not been well studied. Whether the inhibitory effect on NF-κB is 
resulted from interaction of the decoy with cytoplasmic or nuclear NF-κB is not clear. 
Therefore, in our future studies, the subcellular localization of decoy-bound NF-κB will 
be investigated for better understanding the behavior of the decoy in cells. Secondly, 
lysosomes or endosomes have been demonstrated to be involved in the TfR-mediated 
endocytosis, in which the nucleases easily degraded the DNA complex. However, many 
studies including the present study suggested the decoy should successfully escape from 
endosomes or lysosomes as pharmacological effects were observed [248]. Therefore, the 
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intracellular trafficking path of the DNA complex will be investigated to figure out the 
mechanism of endosomal/lysosomal escape.  
The bEnd5 cells will be incubated with fluorescent labeled GS24-NFκB. After incubation 
at 37°C for different time periods, cells will be fixed by 4% paraformaldehyde and 
stained with appropriate antibodies which are used as markers for subcellular 
compartment: anti-EEA1 for early endosomes; anti-Rab4 for recycling endosomes; anti-
Rab7 for late endosomes; anti-lamp-1 for lysosomes. Moreover, Topro-3 iodine and 
Alexa Fluor 488 phalloidin will counter-stain nuclei and actin. The subcellular 
compartments involved in the uptake and trafficking will be identified by colocalization 
of DNA or RNA chimeras with these markers. Scramble GS24-NFκB with scramble 
GS24 will serve as negative controls. 
7.2 Chemical modification of GS24-NFκB  
The pharmacokinetic profile of GS24-NFκB indicated poor stability in blood and rapid 
clearance from circulation, which represent the largest historical obstacle to widespread 
use of aptamer-mediated gene therapy. One strategy that has been widely used to increase 
the serum stability of ODNs is phosphorothioate (PS) modification, which involves 
replacement of non-bridging oxygen atoms in the phosphate group with sulfur [249, 250]. 
The phosphorothioate modification not only enhanced the resistance to nucleases 
compared with phosphodiester (DNA) but also improved distribution and 
pharmacokinetics overall[251]. PS ODNs have higher binding affinity to plasma proteins, 
which may reduce the renal clearance and improve the pharmacokinetics and 
distribution[226]. However, attention should be paid to the toxicity of PS ODNs[252]. 
Partially thiophosphorylated instead of complete substitution is preferred to maximally 
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enhance the stability and limit the toxicity[251]. Blockage of the 3' or 5' ends of aptamers 
with small molecules is another strategy, which successfully reduced enzymatic 
degradation. 3’end capping strategy with inverted thymidine inhibits the predominant 
nuclease degradation in serum, 3’ exonuclease attack and increases the serum half-life 
[253, 254]. In addition, 3’-biotin-streptavidin conjugated ODNs have higher resistance to 
3’ exonuclease and lower clearance in systemic circulation [253, 255]. Conjugation of 
ODNs with polyethylene glycol (PEG) significantly reduces the systemic clearance by 
increasing the molecular size [256, 257].  
The pharmacokinetics of the modified ODNs will be investigated to verify whether the 
modifications improve the biostability and enhance the brain uptake of the DNA 
complex. Attention should be paid to the efficacy of the modified DNA chimera as the 
binding affinity and specificity of the aptamer may be affected by the modified sugars 
especially if internal to the aptamer chain and associated with a binding site[164].  
7.3 Therapeutic effect in vivo 
The therapeutic effect in inhibition of neuroinflammation will be further evaluated. The 
number of the animals involved in behavior test is only four, which is not enough to 
obtain a reliable result. More animals will be tested in this experiments. To verify the 
specific inhibitory effect on NF-κB, another scramble control with GS24 and scramble 
decoy sequence will be used in future study. To evaluate the neuroprotective effect of the 
DNA complex, a variety of experiments can be applied, including assessment of 
neurological deficit, infiltration of immune cells and BBB permeability. To investigate 
the toxicity of the DNA complex, one control group with only DNA injection without 
LPS challenge will be added. 
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Although TfR has been demonstrated to allow noninvasive delivery of various 
therapeutic agents to the brain, the ubiquitous expression of the TfR on peripheral organs 
limits its capability for specific brain delivery and induces side effects in non-brain 
tissues. More specific brain delivery strategy should be developed. Comparison between 
two TfRMAbs, 8D3 and R17, indicated that R17 had better brain specificity as there was 
no uptake in mouse liver[238]. R17 is hypothesized to bind to an epitope that is fully 
expressed at the BBB TfR, but is masked in part at the TfR in mouse liver. It is very 
important to identify such brain-specific epitope and develop aptamers targeting them for 
brain delivery, which will largely improve the therapeutic effect of aptamer-mediated 
gene therapy.  
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